Sucampo Pharmaceuticals Inactive 10-K12 Mar 142013 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2013	Mar. 03, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'Sucampo Pharmaceuticals, Inc.	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	43,998,430	'
Entity Public Float	'	'	$83,900,000
Amendment Flag	'false	'	'
Entity Central Index Key	'0001365216	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$44,102,000	$52,022,000
Investments, current	16,003,000	6,035,000
Product royalties receivable	14,829,000	14,175,000
Unbilled accounts receivable	1,000	732,000
Accounts receivable, net	5,407,000	1,360,000
Prepaid and income taxes receivable	9,000	'
Deferred tax assets, current	2,028,000	874,000
Deferred charge, current	673,000	673,000
Restricted cash, current	26,115,000	15,113,000
Inventory	209,000	'
Prepaid expenses and other current assets	3,977,000	1,930,000
Total current assets	113,353,000	92,914,000
Investments, non-current	7,219,000	14,408,000
Property and equipment, net	1,156,000	1,540,000
Intangible assets, net	6,438,000	7,415,000
Deferred tax assets, non-current	1,212,000	1,654,000
Deferred charge, non-current	4,540,000	5,213,000
Restricted cash, non-current	2,471,000	3,832,000
Other assets	584,000	820,000
Total assets	136,973,000	127,796,000
Current liabilities:	'	'
Accounts payable	7,614,000	5,496,000
Accrued expenses	5,682,000	10,595,000
Deferred revenue, current	1,365,000	3,700,000
Income tax payable	701,000	148,000
Notes payable, current	26,892,000	19,129,000
Other current liabilities	358,000	1,003,000
Total current liabilities	42,612,000	40,071,000
Notes payable, non-current	25,828,000	33,722,000
Deferred revenue, non-current	6,169,000	7,093,000
Deferred tax liability, non-current	2,066,000	2,627,000
Other liabilities	2,150,000	1,253,000
Total liabilities	78,825,000	84,766,000
Commitments and contingencies (Notes 9 and 12)	'	'
Preferred stock, $0.01 par value; 5,000,000 shares authorized at December 31, 2013 and 2012; no shares issued and outstanding at December 31, 2013 and 2012	0	0
Additional paid-in capital	72,109,000	62,521,000
Accumulated other comprehensive income	15,601,000	16,166,000
Treasury stock, at cost; 524,792 and 457,030 shares	-2,313,000	-1,977,000
Accumulated deficit	-27,681,000	-34,100,000
Total stockholders' equity	58,148,000	43,030,000
Total liabilities and stockholders' equity	136,973,000	127,796,000
Common Class A [Member]	'	'
Current liabilities:	'	'
Common stock value	$432,000	$420,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred stock, par value (in Dollars per share)	$0.01	$0.01
Preferred stock,shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury stock, shares	524,792	457,030
Common Class A [Member]	'	'
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	270,000,000	270,000,000
Common stock, shares issued	43,315,749	41,964,905
Common stock, shares outstanding	43,315,749	41,964,905
Common Class B [Member]	'	'
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Research and development revenue	$20,354	$21,545	$9,249
Product royalty revenue	52,100	50,696	41,517
Product sales revenue	16,425	5,037	'
Co-promotion revenue	61	3,576	3,378
Contract and collaboration revenue	654	633	617
Total revenues	89,594	81,487	54,761
Costs and expenses:	'	'	'
Cost of goods sold	12,402	3,030	'
Research and development	21,524	21,292	33,497
Settlement of legal dispute	'	'	-11,100
General and administrative	25,413	30,157	41,270
Selling and marketing	21,059	18,691	8,783
Total costs and expenses	80,398	73,170	72,450
Income (loss) from operations	9,196	8,317	-17,689
Non-operating income (expense):	'	'	'
Interest income	124	179	249
Interest expense	-1,894	-2,346	-2,455
Other income (expense), net	2,921	1,602	-2,019
Total non-operating income (expense), net	1,151	-565	-4,225
Income (loss) before income taxes	10,347	7,752	-21,914
Income tax benefit (provision)	-3,928	-2,916	4,608
Net income (loss)	6,419	4,836	-17,306
Net income (loss) per share:	'	'	'
Basic net income (loss) per share (in Dollars per share)	$0.15	$0.12	($0.41)
Diluted net income (loss) per share (in Dollars per share)	$0.15	$0.12	($0.41)
Weighted average common shares outstanding - basic (in Shares)	41,716	41,660	41,839
Weighted average common shares outstanding - diluted (in Shares)	42,544	41,785	41,839
Net income (loss)	6,419	4,836	-17,306
Other comprehensive income gain (loss):	'	'	'
Unrealized loss on investments, net of tax effect	2	36	-2
Foreign currency translation	-567	-1,724	1,282
Comprehensive income (loss)	$5,854	$3,148	($16,026)

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (USD $)	Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
	Common Class A [Member]	Common Class B [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance, amount at Dec. 31, 2010	$156,000	$262,000	$58,468,000	$16,574,000	'	($21,630,000)	$53,830,000
Balance, shares (in Shares) at Dec. 31, 2010	15,659,917	26,191,050	'	'	'	'	'
Employee stock option expense	'	'	1,370,000	'	'	'	1,370,000
Stock issued upon exercise of stock options	1,000	'	106,000	'	'	'	107,000
Stock issued upon exercise of stock options (in Shares)	27,500	'	'	'	'	'	'
Stock issued under employee stock purchase plan	'	'	13,000	'	'	'	13,000
Stock issued under employee stock purchase plan (in Shares)	3,363	'	'	'	'	'	'
Foreign currency translation	'	'	'	1,282,000	'	'	1,282,000
Unrealized loss on investments, net of tax effect	'	'	'	-2,000	'	'	-2,000
Treasury stock, at cost	'	'	'	'	-700,000	'	-700,000
Treasury stock, at cost (in Shares)	'	'	'	'	186,987	'	'
Net income/loss	'	'	'	'	'	-17,306,000	-17,306,000
Balance, amount at Dec. 31, 2011	157,000	262,000	59,957,000	17,854,000	-700,000	-38,936,000	38,594,000
Balance, shares (in Shares) at Dec. 31, 2011	15,690,780	26,191,050	'	'	186,987	'	'
Conversion of shares	262,000	-262,000	'	'	'	'	'
Conversion of shares (in Shares)	26,191,050	-26,191,050	'	'	'	'	'
Employee stock option expense	'	'	2,233,000	'	'	'	2,233,000
Stock issued upon exercise of stock options	1,000	'	311,000	'	'	'	312,000
Stock issued upon exercise of stock options (in Shares)	79,525	'	'	'	'	'	'
Stock issued under employee stock purchase plan	'	'	20,000	'	'	'	20,000
Stock issued under employee stock purchase plan (in Shares)	3,550	'	'	'	'	'	'
Foreign currency translation	'	'	'	-1,724,000	'	'	-1,724,000
Unrealized loss on investments, net of tax effect	'	'	'	36,000	'	'	36,000
Treasury stock, at cost	'	'	'	'	-1,277,000	'	-1,277,000
Treasury stock, at cost (in Shares)	'	'	'	'	270,043	'	'
Net income/loss	'	'	'	'	'	4,836,000	4,836,000
Balance, amount at Dec. 31, 2012	420,000	'	62,521,000	16,166,000	-1,977,000	-34,100,000	43,030,000
Balance, shares (in Shares) at Dec. 31, 2012	41,964,905	'	'	'	457,030	'	'
Employee stock option expense	'	'	1,744,000	'	'	'	1,744,000
Stock issued upon exercise of stock options	5,000	'	2,332,000	'	'	'	2,337,000
Stock issued upon exercise of stock options (in Shares)	597,836	'	'	'	'	'	'
Stock issued under employee stock purchase plan	'	'	25,000	'	'	'	25,000
Stock issued under employee stock purchase plan (in Shares)	3,625	'	'	'	'	'	'
Stock issued under "at-the-market" offering	7,000	'	5,274,000	'	'	'	5,281,000
Stock issued under "at-the-market" offering (in Shares)	749,383	'	'	'	'	'	'
Foreign currency translation	'	'	'	-567,000	'	'	-567,000
Unrealized loss on investments, net of tax effect	'	'	'	2,000	'	'	2,000
Windfall tax benefit from stock-based compensation	'	'	213,000	'	'	'	213,000
Treasury stock, at cost	'	'	'	'	-336,000	'	-336,000
Treasury stock, at cost (in Shares)	'	'	'	'	67,762	'	'
Net income/loss	'	'	'	'	'	6,419,000	6,419,000
Balance, amount at Dec. 31, 2013	$432,000	'	$72,109,000	$15,601,000	($2,313,000)	($27,681,000)	$58,148,000
Balance, shares (in Shares) at Dec. 31, 2013	43,315,749	'	'	'	524,792	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income (loss)	$6,419	$4,836	($17,306)
Depreciation and amortization	1,488	1,488	1,308
Loss on disposal of property and equipment	'	'	12
Deferred tax provision (benefit)	-1,678	-23,026	26,228
Deferred charge	673	23,922	-29,808
Stock-based compensation	1,744	2,233	1,370
Amortization of premiums on investments	110	67	651
Notes payable paid-in-kind interest	'	2,024	2,288
Unrealized currency translations (gains) losses	-3,232	-1,300	'
Accounts receivable	-4,047	3,256	-3,885
Unbilled accounts receivable	732	1,303	-939
Product royalties receivable	-654	-3,380	-280
Inventory	-163	87	-127
Prepaid and income taxes receivable and payable, net	560	2,998	-2,173
Accounts payable	2,242	-1,453	2,872
Accrued expenses	-4,685	15	523
Deferred revenue	-3,126	-95	-1,940
Accrued interest payable	-32	'	'
Other assets and liabilities, net	-1,769	-975	1,215
Net cash provided by (used in) operating activities	-5,418	12,000	-19,991
Cash flows from investing activities:	'	'	'
Purchases of investments	-10,127	-23,609	-20,598
Proceeds from the sales of investments	755	750	7,380
Maturities of investments	6,485	27,790	46,665
Purchases of property and equipment	-168	-439	-284
Proceeds from disposals of property and equipment	'	'	25
Issuance of notes receivable	'	'	-100
Purchases of intangible assets	'	-3,000	-3,000
Purchase of other investing activities	'	-432	'
Change in restricted cash	-10,826	-1,649	-2,187
Net cash provided by (used in) investing activities	-13,881	-589	27,901
Cash flows from financing activities:	'	'	'
Proceeds from notes payable	10,600	'	'
Repayment of notes payable	-7,539	-7,500	-7,500
Proceeds from exercise of stock options	2,337	311	106
Proceeds from employee stock purchase plan	25	20	13
Proceeds from "at-the market" stock issuance	5,281	'	'
Purchase of treasury stock	-336	-1,277	-700
Windfall tax benefit from stock-based compensation	213	'	'
Net cash provided by (used in) financing activities	10,581	-8,446	-8,081
Effect of exchange rates on cash and cash equivalents	798	-1,605	1,590
Net increase (decrease) in cash and cash equivalents	-7,920	1,360	1,419
Cash and cash equivalents at beginning of period	52,022	50,662	49,243
Cash and cash equivalents at end of period	44,102	52,022	50,662
Supplemental cash flow disclosures:	'	'	'
Cash paid for interest	156	157	171
Tax refunds received	103	3,658	245
Tax payments made	4,939	3,665	1,476
Supplemental disclosure of non-cash investing and financing activities:	'	'	'
Purchase of intangible assets included in accrued expenses	'	'	$3,000

Note_1_Business_Organization_a

Note 1 - Business Organization and Basis of Presentation

12 Months Ended

Dec. 31, 2013

Disclosure Text Block [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Business Organization and Basis of Presentation

Description of the Business

Sucampo Pharmaceuticals, Inc., or the Company, is a global biopharmaceutical company focused on innovative research, discovery, development and commercialization of ion channel activators known as prostones. The therapeutic potential of prostones was first discovered by the Company’s cofounder, Dr. Ryuji Ueno. Dr. Ueno initially found that that prostone production was high in early development, and postulated that prostones produced by 15-PGDH may play important roles as an endogenous local hormones in maturation and aging. Under his leadership the Company has pioneered the field of prostones. Prostones are naturally occurring fatty acid metabolites which originally thought to be biologically inert. Prostones have emerged as a promising compound class with unique physiological activities which can be targeted for the treatment of unmet or underserved medical needs.

Prostones act locally to restore normal function in cells and tissues, and because they are quickly metabolized to an inactive form, their pharmacologic activity can be targeted to specific organs and tissues. Prostones possess a unique mechanism of action as highly potent and selective ion channel activators. Ion channels are integral parts of cell membranes that regulate the flow of specific ions into and out of cells. This regulation is critical for the functioning of metabolic processes and cell survival. As such, prostones are physiological mediators of the restoration of cellular homeostasis and tissue regeneration. There is also evidence that prostones have anti-inflammatory properties and can prevent cell death.

The Company’s prostone-based compounds target the ClC-2 (chloride) and big potassium, or BK, ion channels. Because these ion channels play an important role in physiology, targeted dosing of prostones may have broad applicability in many disease states in different organ systems. The Company has developed synthetic analogs of the naturally occurring prostones, which have been optimized to be more potent, selective, and stable, thus enabling their use as drugs. Prostones are very selective for their molecular targets, and the approved prostone-based compounds are well-tolerated and generally safe.

The Company is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other potential therapeutic applications of the Company’s drug technologies.

The Company currently generates revenue mainly from product royalties, development milestone payments, clinical development activities and product sales. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks regulatory approvals and additional indications for AMITIZA® (lubiprostone), RESCULA® (unoprostone isopropyl) and other compounds, and commercializes the Company’s approved products on a global basis.

To date, two prostone products have received marketing approval, AMITIZA and RESCULA, globally. A third prostone, cobiprostone, is in phase 1b clinical development for the target indication of prevention and/or treatment of oral mucositis, or OM. In April 2013, the Company received approval for a supplemental new drug application, or sNDA, for AMITIZA at dosage strength of 24 micrograms twice daily as the first and only oral medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. Additionally, in December 2013, the Company announced the initiation of the pivotal phase 3 clinical program of AMITIZA in pediatric functional constipation. This is the first of a series of global, multicenter phase 3 studies to evaluate the efficacy, safety, and pharmacokinetics of AMITIZA capsules in patients ≥ 6 months through 17 years of age with pediatric functional constipation. The Company also plans to evaluate the long-term safety of AMITIZA in these populations through two open-label extension studies. One of the pediatric trials will also use the liquid formulation. Lastly, two ion channel activators, in both the intravenous, or IV, and oral, or PO, forms, are in clinical development for the treatment of lumbar spinal stenosis, or LSS. In December 2013, the Company reported results of the treatment phase of the phase 2a, double-blind, placebo-controlled study of the IV version of the Company’s ion channel activator for LSS, that indicated statistically significant improvement in Visual Analog Scale pain. The Company plans to initiate an additional phase 2a in the second half of 2014. The PO ion channel activator for phase 1a clinical development results were reported in August 2013 and demonstrated to be generally well-tolerated. The Company plans to initiate the next phase of clinical development in the first quarter of 2014. Additionally, these compounds may be investigated for other indications.

AMITIZA is being marketed in the United States for three gastrointestinal indications under the October 2004 collaboration and license agreement with Takeda Pharmaceutical Company Limited, or Takeda Agreement. These indications are chronic idiopathic constipation, or CIC, in adults, irritable bowel syndrome with constipation, or IBS-C, in adult women and opioid-induced constipation, or OIC, in adults,. Takeda also holds marketing rights to AMITIZA in Canada, but has not yet commercialized it there. The Company is primarily responsible for clinical development activities under the Takeda Agreement while Takeda is primarily responsible for commercialization of AMITIZA in the United States and Canada. The Company and Takeda initiated commercial sales of AMITIZA in the United States for the treatment of CIC, in April 2006, for the treatment of IBS-C in May 2008 and for the treat of OIC in May 2013.

In Japan, lubiprostone is being developed and marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd., or Abbott, for the treatment of chronic idiopathic constipation, or CIC, in Japan. The Company received approval of its new drug application, or NDA, for AMITIZA for the treatment of chronic constipation, or CC, excluding constipation caused by organic diseases, from the Ministry of Health, Labour and Welfare in June 2012 and pricing approval in November 2012. In November 2012, the Company and Abbott announced the availability of AMITIZA in Japan for CC. In early December 2013, the two-week limitation on prescriptions, generally applied to all new approvals of products for the first year after reimbursement price approval, was removed. AMITIZA is Japan’s only prescription medicine for CC.

In the United Kingdom, the Company received approval in September 2012 from the Medicines and Healthcare Products Regulatory Agency, or MHRA, for the use of AMITIZA to treat CIC. The Company has made AMITIZA available in the United Kingdom in the fourth quarter of 2013 and is currently working to achieve National Institute for Health and Care Excellence endorsement for CIC. In Switzerland, AMITIZA was approved in 2009. In 2012, the Company reached an agreement with the Bundesamt fur Gesundheit, or BAG, on a reimbursement price for AMITIZA in Switzerland, and began active marketing in the first quarter of 2013. Since February 2012, AMITIZA has also been available through a Named Patient Program throughout the European Union, Iceland and Norway. In February 2014, the Company announced that the BAG revised several reimbursement limitations with which AMITIZA was first approved for reimbursement and inclusion in the Specialitätenliste, or SL, to allow all Swiss physicians to prescribe AMITIZA to patients who have failed previous treatments with at least two laxatives over a nine month period.

The Company filed for the OIC indication in Switzerland in the first quarter of 2013, and anticipates a decision in the first half of 2014. On March 7, 2014, MHRA notified the Company that the application for approval of the OIC indication in the United Kingdom was not approved. The Company is considering the appropriate next steps with MHRA. The Company is considering seeking approval for AMITIZA in other European Union countries following the Mutual Recognition Procedure, or MRP.

The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. A sNDA for RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure, or IOP, in patients with open-angle glaucoma or ocular hypertension was approved by the FDA in December 2012 and the Company began commercializing the product in February 2013. According to the approved product labeling, RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator, which is different from other IOP lowering agents.

In other areas of development, the Company entered into an agreement in 2011 with Numab AG, or Numab, to obtain access to their proprietary technology for the discovery of high-affinity antibodies against certain selected targets. In October 2013, Numab and the Company entered into a termination arrangement which will result in continued development by Numab. After successful development by Numab and an agreement with a third party investor, Numab and the Company will enter into a license agreement on commercially reasonable terms.

Basis of Presentation

The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the rules and regulations of the Securities and Exchange Commission, or SEC. The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG, or SAG, based in Zug, Switzerland, in which the company conducts certain worldwide and European operations; Sucampo Pharma, Ltd., or SPL, based in Tokyo and Osaka, Japan, in which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, or SPA, based in Bethesda, Maryland, in which the Company conducts operations in North and South America; Sucampo Pharma Europe, Ltd., or SPE, based in Oxford, United Kingdom, and Ambrent Investments S.à r.l., based in Luxembourg which conduct operations in Europe. All significant inter-company balances and transactions have been eliminated.

The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Revision to Previously Issued Financial Statements

The Company has revised the December 31, 2012 consolidated statements of operations and comprehensive income to correct an error in the improper presentation of gross profit. As a result of this revision, gross profit will be removed as a sub-total and cost of goods sold will be disclosed as an operating cost under the heading “Costs and expenses”. Gross profit was presented on the consolidated statements of operations and comprehensive income beginning in the period ended December 31, 2012 and for periods ended March 31, June 30 and September 30, 2013. The revision has no impact on income from operations or net income and was determined to not be material to any previously issued financial statements. Accordingly, the Company will revise previously reported interim periods in future filings. The following revision has been made to the previously reported December 31, 2012 balances:

Presentation as of December 31, 2012

(In thousands)

As Previously

Revision

Reported

Adjustment

Revised

Gross profit

78,457

(78,457

)

Total costs and expenses

(70,140

)

(3,030

)

(73,170

)

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

For the purpose of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity of 90 days or less at the time of purchase.

Restricted Cash

Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd. (the Tokyo-Mitsubishi Bank); a loan agreement with The Mizuho Bank, Ltd. (the Mizuho Bank); a loan agreement between Numab AG (Numab) and Zurcher Kantonalbank, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.6 million and $18.9 million at December 31, 2013 and 2012, respectively.

Current and Non-Current Investments

Current and non-current investments consist primarily of United States government agency securities, certificates of deposit, corporate bonds, municipal securities and variable rate demand notes, and are classified as current or non-current based on their maturity dates. The Company classifies all investments as available-for-sale securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income.

Certain Risks, Concentrations and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of December 31, 2013 and 2012, approximately $16.4 million, or 17.1%, and $16.8 million, or 18.4%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.

The Company’s products and product candidates under development require approval from the FDA or other international regulatory agencies prior to commercial sales. For those product candidates or indications that have not yet been approved by the FDA or international regulatory agencies, there can be no assurance the products will receive the necessary approval. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company.

The Company’s products, AMITIZA and RESCULA, compete in a rapidly changing, highly competitive market, which is characterized by advances in scientific discovery, changes in customer requirements, evolving regulatory requirements and developing industry standards. Any failure by the Company to anticipate or to respond adequately or timely to scientific developments in its industry, changes in customer requirements or changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of products could have a material adverse effect on the Company’s business, operating results and future cash flows.

The Company’s expected activities may necessitate significant uses of working capital. The Company’s working capital requirements will depend on many factors, including the successful sales of AMITIZA and RESCULA, research and development efforts to develop new products or indications, payments received under contractual agreements with other parties, the status of competitive products and market acceptance of the Company’s new products by physicians and patients. The Company plans to continue financing operations with its existing cash and investments as well as with product royalty revenue and cash received from milestones and other revenue related to its joint collaboration, license and supply agreements.

Revenues from Takeda, an unrelated party, accounted for 81.3%, 74.4% and 96.9%, of the Company’s total revenues for the years ended December 31, 2013, 2012 and 2011, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 88.2% and 98.0% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at December 31, 2013 and 2012. Revenues from another unrelated party, Abbott, accounted for 17.6%, 19.3% and 2.3% of the Company’s total revenues for the years ended December 31, 2013, 2012 and 2011. The Company depends significantly upon collaborations with Takeda and Abbott, and its activities may be impacted if these relationships are disrupted (Note 13).

The Company has an exclusive supply arrangement with R-Tech Ueno, Ltd, or R-Tech, to provide the Company with commercial and clinical supplies of its product and product candidates. R-Tech also provides certain preclinical and other research and development services. Any difficulties or delays in performing the services under these arrangements may cause the Company to lose revenues, delay research and development activities or otherwise disrupt the Company’s operations (see Note 10).

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the notes payable at December 31, 2013 and 2012 were less than the estimated fair values (see Note 11.) The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, and is classified as a Level 2 security.

Accounts Receivable and Unbilled Accounts Receivable

Accounts receivable primarily represent amounts due under the Takeda and Abbott Agreements. Unbilled accounts receivable consist of research and development expenses that are reimbursable by Takeda, but as of the balance sheet date have not been billed to Takeda. The Company recorded an allowance for doubtful accounts of approximately $440,000 and $280,000 at December 31, 2013 and 2012, respectively, related to certain disputed Takeda invoices.

Product Royalties Receivable

Product royalties receivable represent amounts due from Takeda for the Company’s royalties on sales of AMITIZA, which are based on reports obtained directly from Takeda.

Inventory

Inventory is stated at cost or market, whichever is lower. Cost is determined on a first-in, first-out basis. Inventory is reviewed periodically for potential excess, dated or obsolete status. The Company’s management evaluates the carrying value of inventory on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the prices the Company expects to obtain for products in their respective markets compared to historical costs, and the remaining shelf life of goods on hand.

Property and Equipment

Property and equipment are recorded at cost and consist of computer and office machines, furniture and fixtures, and leasehold improvements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer and office machines are depreciated over four years and furniture and fixtures are depreciated over seven years. Leasehold improvements are amortized over the shorter of ten years or the life of the lease. Significant additions and improvements are capitalized. Expenditures for maintenance and repairs are charged to earnings as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in earnings.

Impairment Evaluation for Long-lived Assets

When necessary, the Company assesses the recoverability of its long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, the Company measures the amount of such impairment by comparing the fair value to the carrying value. There have been no impairment charges recorded during the years ended December 31, 2013, 2012 or 2011 because there have been no indicators of impairment during those years.

Revenue Recognition

The Company’s revenues are derived primarily from product royalties, development milestone payments, clinical development activities and product sales.

Research and Development Revenue

The Company evaluated the multiple deliverables within the collaboration and license agreements in accordance with the guidance of multiple deliverables to determine whether the delivered elements that are the obligation of the Company have value to other parties to the agreement on a stand-alone basis and whether objective reliable evidence of fair value of the undelivered items exists. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting. The appropriate recognition of revenue is then applied to each separate unit of accounting. The Company’s deliverables under the Takeda Agreement and Abbott Agreement, including the related rights and obligations, contractual cash flows and performance periods, are more fully described in Note 12 below.

Where agreements include contingent milestones the Company evaluates whether each milestone is substantive. Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Where milestones are not considered substantive their treatment is based on either a time-based or proportional performance model.

The Company applies a time-based model of revenue recognition for cash flows associated with research and development deliverables agreed upon prior to January 1, 2011 under the Takeda Agreement. Under this model, cash flow streams related to each unit of accounting are recognized as revenue over the estimated performance period. Upon receipt of cash payments, such as development milestones, revenue is recognized to the extent the accumulated service time has occurred. The remainder is deferred and recognized as revenue ratably over the remaining estimated performance period. A change in the period of time expected to complete the deliverable is accounted for as a change in estimate on a prospective basis. In cases where milestone payments are received after the completion of the associated development period, the Company recognizes revenue upon completion of the performance obligation. Revenue is limited to amounts that are nonrefundable and that the other party to the agreement is contractually obligated to pay to the Company. The research and development revenue for these obligations is limited to the lesser of the actual reimbursable costs incurred or the straight-line amount of revenue recognized over the estimated performance period. Revenues are recognized for reimbursable costs only if those costs can be reasonably determined.

For research and development deliverables agreed upon subsequent to January 1, 2011 which are reimbursable by Takeda at contractually predetermined percentages, the Company recognizes revenue when the underlying research and development expenses are incurred, assuming all other revenue recognition criteria are met.

The Company applies a proportional-performance model using the percentage-of-completion method of revenue recognition for cash flows associated with research and development deliverables under the Abbott Agreement. Since the Company has previous research and development experience and the expected cost to complete the development can be reasonably estimated, the Company believes a proportional-performance methodology of revenue recognition is appropriate. Under this method, revenue in any period is recognized as a percentage of the total actual cost expended relative to the total estimated costs required to satisfy the performance obligations under the arrangement related to the development. Revenue recognized is limited to the amounts that are non-refundable and that the other party to the agreement is contractually obligated to pay to the Company. A change in the period of time expected to complete the deliverable is accounted for as a change in estimate on a prospective basis. Research and development costs are not reimbursable under the Abbott Agreement.

Contract revenue relates to development and consulting activities and is accounted for under the time-based model.

Product Royalty Revenue

Royalty revenues are based on net sales of licensed products and are recorded on an accrual basis when earned in accordance with contractual terms if third-party results are reliably measurable, collectability is reasonably assured and all other revenue recognition criteria are met.

Product Sales Revenue

AMITIZA product sales consist of AMITIZA sales to Abbott in Japan and by the Company in Europe. Revenue from AMITIZA product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. The Company did not record sales deductions and returns for sales of AMITIZA due to the absence of discounts and rebates and the lack of right of return.

RESCULA product sales consist of RESCULA sales in the United States. The Company recognizes revenue from RESCULA product sales less deductions for estimated sales discounts and sales returns. Revenue from product sales of RESCULA is recognized when persuasive evidence of an arrangement exists, title passes, the price is fixed or determinable, and collectability is reasonably assured. The Company accounts for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. As a result, the Company estimates an accrual for product returns, which is recorded as a reduction of product sales. Given the Company’s limited history of selling RESCULA and the return period, the Company cannot reasonably estimate product returns from the wholesale distribution channel. Therefore, the Company is deferring the recognition of revenue until there is confirmation of pull-through sales to end-user customers. The Company will continue to defer recognition until the point at which the Company has obtained sufficient sales history to reasonably estimate returns from the wholesalers. The Company’s three largest wholesale customers accounted for 96.2% of its RESCULA product sales for the year ended December 31, 2013.

Co-promotion Revenue

Co-promotion revenue relates to a limited reimbursement of co-promotion costs based on details to healthcare prescribers.

Contract and Collaboration Revenue

Contract revenue relates to development and consulting activities and is accounted for under the time-based model.

The Company considers its participation in joint committees under its collaboration and license agreements as separate deliverables under the contracts and recognizes the fair value of such participation as collaboration revenue over the period of the participation per the terms of the contracts.

The Company has determined that it is acting as a principal under both the Takeda Agreement and the Abbott Agreement and, as such, records revenue on a gross basis in the Condensed Consolidated Statements of Comprehensive Income (Loss).

Deferred Revenue

Deferred revenue represents payments received for licensing fees, option fees, consulting, research and development contracts and related cost sharing and supply agreements, mainly with Takeda, Abbott and R-Tech, which are deferred until revenue can be recognized under the Company’s revenue recognition policy. Deferred revenue is classified as current if management believes the Company will be able to recognize the deferred amount as revenue within 12 months of the balance sheet date. At December 31, 2013 and 2012, total deferred revenue was approximately $7.5 million and $10.8 million, respectively.

Total deferred revenue consists of the following as of:

December 31,

(In thousands)

2013

2012

Deferred revenue, current

1,365

3,700

Deferred revenue, non-current

6,169

7,093

7,534

10,793

Deferred revenue to related parties, included in total deferred revenue:

Deferred revenue to related parties, current

477

479

Deferred revenue to related parties, non-current

4,925

5,386

Total

5,402

5,865

Cost of Goods Sold

Cost of goods sold relates to purchase and distribution costs of the products sold by the Company, including inventory write-offs for excess and obsolete inventory and amortization of marketing licenses.

Research and Development Expenses

Research and development costs are expensed in the period in which they are incurred and include the expenses from third parties who conduct research and development activities pursuant to development and consulting agreements on behalf of the Company. Costs related to the acquisition of intellectual property are expensed as incurred in research and development expenses since the underlying technology associated with such acquisitions is unproven, has not received regulatory approval at its early stage of development and does not have alternative future uses. Milestone payments due under agreements with third party contract research organizations, or CROs, are accrued when it is considered probable that the milestone event will be achieved.

General and Administrative Expenses

General and administrative costs are expensed as incurred and consist primarily of salaries and other related costs for personnel serving executive, finance, accounting, information technology and human resource functions. Other costs include facility costs and professional fees for legal and accounting services.

Selling and Marketing Expenses

Selling and marketing expenses represent costs the Company incurs to co-promote AMITIZA and promote RESCULA, including salaries, benefits and related costs of the Company’s sales force and other sales and marketing personnel, costs of market research and analysis and other selling and marketing expenses.

Interest Income

Interest income consists of interest earned on the Company’s cash and cash equivalents and current and non-current investments.

Accrued Research and Development Expenses

As part of the process of preparing Consolidated Financial Statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company’s behalf and determining the value of these services. Examples of these services are payments to clinical investigators and contract service organizations. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external CROs and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment; invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes significant judgments and estimates in determining the accrued balance in any accounting period. No material adjustments have been required for this accrual during the years ended December 31, 2013 and 2012.

Employee Stock-Based Compensation

The Company applied accounting guidance for share-based awards that requires the measurement and recognition of expense for all share-based compensation of employees and directors to be based on estimated fair values of the share-based awards. This guidance requires companies to estimate the fair value of share-based awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service period in the Company’s consolidated statement of operations.

The Company’s determination of fair value of share-based awards on the date of grant using an option-pricing model is affected by the Company’s stock price and assumptions regarding a number of highly complex and subjective variables.

The assumptions used to estimate the fair value of stock options granted for the three years ended December 31, 2013 were as follows:

Year Ended December 31,

2013

2012

2011

Expected volatility

65%

75%

62%

64%

55%

64%

Risk-free interest rate

1.23%

1.40%

0.76%

1.60%

1.30%

3.30%

Expected term (in years)

5.5

6.25

5.5

6.25

2.1

6.25

Expected dividend yield

Expected Volatility: The Company evaluated the assumptions used to estimate expected volatility, including whether implied volatility of its options appropriately reflects the market’s expectations of future volatility. The Company determined that it would calculate the expected volatility rate using historical stock prices obtained from comparable publicly-traded companies due to the limited history of the Company’s common stock activity.

Risk-Free Interest Rate: The risk-free interest rate is based on the market yield currently available on United States Treasury securities with a maturity that approximates the expected term of the share-based awards.

Expected Term: The Company elected to use the “simplified” method to calculate its expected term of share-based awards. Under this method, the expected term is the weighted average of the vesting term and the contractual term. The Company has used a lattice based model to determine the expected term for its market condition share-based awards.

Expected Dividend Yield: The Company has not paid, and does not anticipate paying, any dividends in the foreseeable future.

Employee stock-based compensation expense for the three years ended December 31, 2013 has been reduced for estimated forfeitures as such expense is based upon awards expected to ultimately vest. Accounting guidance on share-based payments requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the years ended December 31, 2013, 2012 and 2011, the estimated forfeiture rate ranged from 10.0% to 14.0%.

Employee stock-based compensation expense recorded in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) for the three years ended December 31, 2013 was as follows:

Year Ended December 31,

(In thousands)

2013

2012

2011

Research and development expense

293

535

234

General and administrative expense

1,260

1,349

964

Selling and marketing expense

191

349

172

Total

1,744

2,233

1,370

Employee stock-based compensation expense per basic and diluted share of common stock

0.04

0.05

0.03

Income Taxes

The Company accounts for income taxes under the asset and liability method in accordance with the relevant accounting guidance for income taxes. Under the asset and liability method, the current income tax provision or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in the income tax provision during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss, or NOL, carry-forwards that can be utilized in the future to offset taxable income.

In September 2011, the Company internally transferred certain intellectual property and licenses from the Company’s subsidiaries, including the United States based subsidiary, to SAG. Since the transfer of these assets was to a related party, the recognition of a deferred tax asset by SAG is prohibited and the net tax effect of the transaction is deferred in consolidation. The tax liability generated from this transaction is offset by a deferred charge that is being amortized over ten years. Following the decision of the International Court of Arbitration of the International Chamber of Commerce on the Takeda Agreement in July 2012, the Company determined that the internal transfer of the intellectual property was only partially complete and is continuing to evaluate whether the United States rights related to AMITIZA will transfer to SAG in the future. This resulted in a reassessment of the deferred charge, deferred tax liability and the mix of profits and losses earned in each jurisdiction. For the year ended December 31, 2012, the Company recorded a benefit of approximately $1.9 million related to the partial reversal of the internal transfer and reduced the deferred charge and deferred tax liability by approximately $23.8 million and $24.1 million, respectively. As of December 31, 2013 and 2012, the total deferred charge is $5.2 million and $5.9 million after a net current year amortization expense of $673,000 and $77,000, respectively.

For all significant intercompany transactions, the Company’s management has evaluated the terms of the transactions using significant estimates and judgments to ensure that each significant transaction would be on similar terms if the Company completed the transaction with an unrelated party. Although the Company believes there will be no material tax liabilities to the Company as a result of multi-jurisdictional transactions, there can be no assurance that taxing authorities will not assert that transactions were entered into at monetary values other than fair values. If such assertions were made, the Company’s intention would be to vigorously defend its positions; however, there can be no assurance that additional liabilities may not occur as a result of any such assertions.

Uncertain Tax Positions

The Company applies the accounting guidance for uncertain tax positions that requires the application of a more likely than not threshold to the recognition and de-recognition of uncertain tax positions. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that, in its judgment, is more than 50% likely to be realized upon settlement.

The Company has recorded an income tax liability of approximately $679,000 and $1.1 million, including interest, for uncertain tax positions as of December 31, 2013 and 2012, respectively. As of December 31, 2013, $42,000 and $637,000 are reflected as other current liabilities and other liabilities, respectively, in the accompanying Consolidated Balance Sheets. As of December 31, 2012, $660,000 and $471,000 are reflected as other current liabilities and other liabilities, respectively, in the accompanying Consolidated Balance Sheets. These amounts represent the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Consolidated Financial Statements. The liability for uncertain tax positions as of December 31, 2013 and 2012 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes, as well as uncertain tax positions related to related party interest in foreign jurisdictions. During the twelve months ended December 31, 2013, the liability for income taxes has decreased approximately $452,000. This decrease in the liability is related primarily to settlement of prior periods with state tax authorities, offset by a net increase related to current year activity in the United States and revisions to prior year estimates.

The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company expects to settle prior periods with state tax authorities; therefore, the amount of $42,000 expected to reverse within the next twelve months has been recorded as a current liability. Other than the expected settlement of tax liabilities, no additional uncertain tax positions have been identified for which it is reasonably possible that the total amount of liability for unrecognized tax benefits will significantly increase or decrease within 12 months, except for recurring accruals on existing uncertain tax positions. In addition, future changes in the unrecognized tax benefits would have an effect on the effective tax rate when recognized.

Currently, tax years 2010, 2011, 2012 and 2013 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed.

Deferred Charge

Certain intellectual property was transferred within the group resulting in a gain in the sellers’ tax jurisdiction and a difference in the buyer’s tax jurisdiction between the new tax basis and the carrying amount of those assets. The FASB guidance on income taxes precludes the Company from including the effects of any intercompany transfers in the financial statements, and so the net tax effect of an intercompany transaction is deferred in consolidation.

These deferred tax effects include the reversal of any existing deferred tax asset (and its related valuation allowance, if any) or liability and any taxes currently payable resulting from the intercompany transaction when the asset remains in the consolidated group for financial reporting purposes. This deferred effect is not the result of a temporary difference and is therefore classified as a deferred charge on the Consolidated Balance Sheet separate from the Company's deferred tax assets.

Since the deferred charge is not part of the deferred tax assets, it is not subject to revaluation for tax rate changes and realizability as prescribed by the FASB’s guidance on income taxes. Thus, the deferred charge will remain fixed and will be amortized over the determined life of 10 years and be included as part of the provision for income taxes as a permanent difference.

Foreign Currency

The Company translates the assets and liabilities of its foreign subsidiaries into U.S. Dollars at the current exchange rate in effect at the end of the year and maintains the capital accounts of these subsidiaries at the historical exchange rates. The revenue, income and expense accounts of the foreign subsidiaries are translated into U.S. Dollars at the average rates that prevailed during the relevant period. The gains and losses that results from this process are included in accumulated other comprehensive income in the stockholders’ equity section of the balance sheet.

Realized and unrealized foreign currency gains or losses on assets and liabilities denominated in a currency other than the functional currency are included in net income.

Other Comprehensive Income

Comprehensive income consists of net income plus certain other items that are recorded directly to stockholders’ equity. The Company has reported comprehensive income in the Consolidated Statements of Operations and Comprehensive Income (Loss).

The Company has outstanding intercompany loans and investments between its subsidiaries which are eliminated for purposes of the Consolidated Financial Statements. These intercompany loans are not expected to be repaid or settled in the foreseeable future. Accordingly, the currency transaction gains or losses on these intercompany loans are recorded as part of other comprehensive income in the Consolidated Financial Statements.

Segment Information

Management has determined that the Company has three reportable segments, which are based on its method of internal reporting by geographical location. The Company’s reportable segments are the Americas, Europe and Asia.

Recent Accounting Pronouncements

In February 2013, the FASB issued an accounting update on Comprehensive Income-Topic 220: Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income, which requires the Company to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, the Company is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under United States GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under United States GAAP to be reclassified in their entirety to net income, the Company is required to cross-reference to other disclosures required under United States GAAP that provide additional detail about those amounts. The Company adopted this update effective January 1, 2013, and such adoption did not have a material impact on the Company's consolidated financial statements.

In July 2013, the FASB issued an Accounting Standards Update, or ASU, providing guidance on whether an uncertain tax position should be presented as a reduction to a deferred tax asset or as a separate liability. This guidance seeks to address diversity in practice. The adoption of this ASU amendment is not expected to have a material effect on the Company’s financial condition, results of operations or cash flows.

Note_3_Net_Income_Loss_per_Sha

Note 3 - Net Income (Loss) per Share	12 Months Ended
Note 3 - Net Income (Loss) per Share	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	3. Net Income (Loss) per Share

	Basic net income (loss) per share is computed by dividing net income (loss) by the sum of the weighted average class A and B common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share.

	The computation of net income (loss) per share for the three years ended December 31, 2013, is shown below:

		December 31,
	(in thousands, except per share data)	2013		2012		2011
	Basic net income (loss) per share:
	Net income (loss)	$	6,419	$	4,836	$	(17,306	)

	Weighted average class A and B common shares outstanding		41,716		41,660		41,839

	Basic net income (loss) per share	$	0.15	$	0.12	$	(0.41	)

	Diluted net income (loss) per share:
	Net income (loss)	$	6,419	$	4,836	$	(17,306	)

	Weighted average class A and B common shares outstanding for diluted net income per share		41,716		41,660		41,839

	Assumed exercise of stock options under the treasury stock method		828		125		-
			42,544		41,785		41,839

	Diluted net income (loss) per share	$	0.15	$	0.12	$	(0.41	)

	The potentially dilutive securities used in the calculations of diluted net income per share at December 31, 2013, 2012 and 2011 are as follows:

		December 31,
	(In thousands)	2013		2012		2011
	Employee stock options		2,129		2,811		-
	Non-employee stock options		410		450		-

	The following securities were excluded from the computation of diluted net income (loss) per share as their effect would be anti-dilutive as of December 31, 2013, 2012 and 2011:

		December 31,
	(In thousands)	2013		2012		2011
	Employee stock options		530		596		3,595
	Non-employee stock options		-		-		450

Note_4_Current_and_NonCurrent_

Note 4 - Current and Non-Current Investments	12 Months Ended
Note 4 - Current and Non-Current Investments	Dec. 31, 2013
Investments Schedule [Abstract]	'
Investment [Text Block]	'
	4. Current and Non-Current Investments

	At December 31, 2013 and 2012, current and non-current investments consisted of the following securities:

			31-Dec-13
	(In thousands)		Cost			Unrealized			Unrealized				Fair Value
	(In thousands)		Cost			Gains			Losses				Fair Value
	Current:
	U.S. government securities		$	1,000		$	-		$	-			$	1,000
	U.S. government agencies			9,048			3			-				9,051
	Certificates of deposits			3,500			-			-				3,500
	Corporate bonds			752			-			-				752
	Municipal securities			1,700			-			-				1,700
	Total		$	16,000		$	3		$	-			$	16,003

	Non-current:
	U.S. government agencies		$	4,212		$	-		$	(3	)		$	4,209
	Certificates of deposits		$	2,500									$	2,500
	Corporate bonds			511			-			(1	)			510
	Total		$	7,223		$	-		$	(4	)		$	7,219

			31-Dec-12
	(In thousands)		Cost			Unrealized			Unrealized				Fair Value
	(In thousands)		Cost			Gains			Losses				Fair Value
	Current:
	U.S. commercial paper		$	2,499		$	-		$	-			$	2,499
	U.S. government securities			251			-			-				251
	Corporate bonds			500			-			-				500
	Variable rate demand notes			2,785			-			-				2,785
	Total		$	6,035		$	-		$	-			$	6,035

	Non-current:
	U.S. government securities		$	10,131		$	2		$	(3	)		$	10,130
	Certificates of deposits			3,000			-			-				3,000
	Corporate bonds			1,281			-			(3	)			1,278
	Total		$	14,412		$	2		$	(6	)		$	14,408

	The Company performs fair value measurements in accordance with the FASB’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:

	Level 1: quoted prices in active markets for identical assets or liabilities;

	Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or

	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

	The Company’s assets measured at fair value on a recurring basis, including cash equivalents, which are subject to the fair value disclosure requirements, are as follows:

			Fair Value Measurements at Reporting Date Using
	31-Dec-13		Quoted Prices			Significant			Significant
			in Active			Other			Unobservable
			Markets for			Observable			Inputs
			Identical			Inputs
			Assets
	(In thousands)		(Level 1)			(Level 2)			(Level 3)				Total
	U.S. government securities		$	-		$	1,000		$	-			$	1,000
	U.S. government agencies			-			13,260			-				13,260
	U.S. commercial paper			-			6,449			-				6,449
	Municipal securities			-			1,700			-				1,700
	Certificates of deposits			-			6,000			-				6,000
	Corporate bonds			-			5,533			-				5,533
	Money market funds			5,955			-			-				5,955
	Total assets measured at fair value		$	5,955		$	33,942		$	-			$	39,897

		Fair Value Measurements at Reporting Date Using
31-Dec-12		Quoted Prices			Significant			Significant
		in Active			Other			Unobservable
		Markets for			Observable			Inputs
		Identical			Inputs
		Assets
(In thousands)		(Level 1)			(Level 2)			(Level 3)				Total
U.S. government securities		$	-		$	10,130		$	-			$	10,130
U.S. commercial paper			-			5,998			-				5,998
Municipal securities			-			1,253			-				1,253
Certificates of deposits			-			3,500			-				3,500
Corporate bonds			-			6,286			-				6,286
Money market funds			16,274			-			-				16,274
Variable rate demand notes			-			2,785			-				2,785
Total assets measured at fair value		$	16,274		$	29,952		$	-			$	46,226

If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.

Note_5_Property_and_Equipment

Note 5 - Property and Equipment	12 Months Ended
Note 5 - Property and Equipment	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	5. Property and Equipment

	Property and equipment consists of the following:

		December 31,
	(In thousands)	2013			2012
	Computer and office machines	$	2,607		$	2,598
	Furniture and fixtures		480			434
	Leasehold improvements		1,444			1,478
	Total cost		4,531			4,510
	Less: accumulated depreciation		(3,375	)		(2,970	)
	Total	$	1,156		$	1,540

	Depreciation expense for the years ended December 31, 2013, 2012 and 2011 was approximately $512,000, $542,000 and $591,000, respectively.

	The leasehold improvements as of December 31, 2013 and 2012 are tenant improvements to the Company’s headquarters in Bethesda, Maryland.

Note_6_Intangible_Assets

Note 6 - Intangible Assets	12 Months Ended
Note 6 - Intangible Assets	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	6. Intangible Assets

	In April 2009, the Company entered into an agreement with R-Tech, or the 2009 R-Tech Agreement, to license all patents and other intellectual property rights related to RESCULA for its FDA approved indication and any new indications for unoprostone isopropyl in the United States and Canada. A sNDA for RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension was approved by the FDA in December 2012 and the Company began commercializing the product in February, 2013. According to the approved product labeling, RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK, or Big Potassium, channel activator, which is different from other IOP lowering agents.

	Under the terms of the 2009 R-Tech Agreement, the Company made an upfront and milestone payments of $3.5 million and may be required to pay up to $5.0 million in additional milestone payments based on the achievement of specified development and commercialization goals. The Company allocated the acquisition cost between an intangible asset of $3.4 million and a non-current prepaid inventory of $85,000. The $3.4 million intangible asset is included in other non-current assets in the accompanying Condensed Consolidated Balance Sheets as of December 31, 2013 and 2012. The non-current prepaid inventory of $85,000 was written-off during the year ended December 31, 2013. Upon the February 2013 RESCULA re-launch, a $500,000 milestone payment was paid to R-Tech in May 2013. The cost is being amortized over the 10-year life of the 2009 R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $341,000 for each of the years ended December 31, 2013, 2012 and 2011. The annual amortization expense will be approximately $341,000 through April 2019. The unamortized amount included in intangible assets was $1.8 million and $2.1 million at December 31, 2013 and 2012, respectively

	On March 22, 2011, the Company entered into a license agreement with R-Tech for unoprostone isopropyl, or the 2011 R-Tech Agreement, expanding the Company’s development and commercialization rights as well as its territories beyond their previously agreed territory of the United States and Canada to the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is now evaluating the opportunities to obtain an appropriate label in the E.U. and other European countries, and the timing of seeking reauthorization in those countries to commercialize unoprostone isopropyl.

	Pursuant to the 2011 R-Tech Agreement, the Company has made payments to R-Tech of $6.0 million, which is reflected in other non-current assets in the accompanying Condensed Consolidated Balance Sheets, and may be required to pay up to $100.0 million in additional milestone payments to R-Tech based on the achievement of specified development and commercialization goals. The Company will be responsible for all development, regulatory, and commercialization activities. The Company is amortizing the $6.0 million over the 10-year life of the R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $613,000 for each of the years ended December 31, 2013, 2012 and 2011, respectively. The annual amortization expense will be approximately $613,000 through March 2021. The unamortized amount included in intangible assets was $4.4 million and $4.9 million at December 31, 2013 and 2012, respectively.

	The Company reviews intangible assets for impairment when events or changes in circumstances indicate that the carrying value of its intangible assets may not be recoverable. An impairment in the carrying value of an intangible asset is recognized whenever anticipated future undiscounted cash flows from an intangible asset are estimated to be less than its carrying value. There have been no impairment charges recorded during the years ended December 31, 2013, 2012 or 2011 because there have been no indicators of impairment during those years. If the Company's actual results, or the plans and estimates used in future impairment analyses, are lower than the original estimates used to assess the recoverability of these assets, the Company could incur future impairment charges.

Note_7_Accrued_Expenses

Note 7 - Accrued Expenses	12 Months Ended
Note 7 - Accrued Expenses	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	7. Accrued Expenses

	Accrued expenses consist of the following:

		December 31,
	(In thousands)	2013		2012
	Research and development costs	$	1,775	$	6,662
	Employee compensation		2,531		1,219
	Selling and marketing costs		584		487
	Legal service fees		14		830
	RESCULA milestones		-		500
	Other accrued expenses		778		897
	Total	$	5,682	$	10,595

Note_8_Other_Liabilities

Note 8 - Other Liabilities	12 Months Ended
Note 8 - Other Liabilities	Dec. 31, 2013
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]	'
Other Liabilities Disclosure [Text Block]	'
	8. Other Liabilities

	Other liabilities consist of the following:

		December 31,
	(In thousands)	2013		2012
	Japan consumption tax payable	$	917	$	-
	Deferred leasehold incentive		255		373
	Deferred rent expense		341		408
	Other liabilities		637		472
	Total	$	2,150	$	1,253

Note_9_Commitments_and_Conting

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	9. Commitments and Contingencies

	Operating Leases

	The Company leases office space in the United States, Switzerland, and Japan, under operating leases through 2017. At December 31, 2013, total future minimum, non-cancelable lease payments under operating leases are as follows:

	(In thousands of U.S. dollars)	December 31,
		2013
	2014	$	1,273
	2015		1,093
	2016		1,084
	2017		139
	2018		-
	Total minimum lease payments	$	3,589

	Rent expense for all operating leases was $1.3 million, $1.6 million and $1.6 million for the years ended December 31, 2013, 2012 and 2011, respectively.

	Research and Development Costs

	The Company routinely enters into agreements with third-party CROs to oversee clinical research and development studies provided on an outsourced basis and assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. Total future estimated costs through 2016 under these agreements as of December 31, 2013 were approximately $6.8 million.

	The maximum contingent liability under the Numab Agreement (see Note 12 below) in the event that Numab defaults under its loan with Zurcher Kantonalbank is $2.5 million. As of December 31, 2013, the potential amount of payments in the event of Numab’s default is $2.2 million.

Note_10_Related_Party_Transact

Note 10 - Related Party Transactions	12 Months Ended
Note 10 - Related Party Transactions	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	10. Related Party Transactions

	R-Tech Ueno, Ltd.

	On March 7, 2003, the Company entered into an exclusive supply agreement with R-Tech. This agreement grants R-Tech the exclusive right to manufacture and supply RUG-015, a prostone compound, and lubiprostone in the United States and Canada, and in consideration for such right R-Tech agreed to pay the Company as follows: $1.0 million upon execution of the agreement, $2.0 million upon commencement of the first phase 2 lubiprostone trial, $3.0 million upon commencement of the first phase 2 RUG-015 trial and $2.0 million upon commencement of the earlier of a second phase 2 or a first phase 3 RUG-015 trial. Upon execution of the agreement, the Company had already commenced phase 2 clinical trials for RUG-015 and lubiprostone, which resulted in an immediate payment of $6.0 million – $1.0 million for the agreement execution, $2.0 million for the commencement of the first phase 2 lubiprostone trial, and $3.0 million for the commencement of the first phase 2 RUG-015 trial. The Company evaluated the $6.0 million in cash receipts from R-Tech and determined the payments were made for the exclusive right to supply inventory to the Company and determined that the amounts should be deferred until commercialization of the drugs begins since this is the point at which the underlying services would commence. Management also was unable to adequately assign value between the two compounds based on the information available to the Company and determined that the full $6.0 million deferred amount would be amortized over the contractual life of the relationship which was equivalent to the estimated commercialization periods of both RUG-015 and lubiprostone (estimated to be through December 2020).

	During the year ended December 31, 2005, the Company ceased the development of RUG-015 due to less than satisfactory phase 2 results and the Company’s Board of Directors, or Board, approved the Company’s decision to discontinue the development of RUG-015. In addition to the Company’s Board, R-Tech also formally approved the abandonment of RUG-015, which was a requirement in the supply agreement terms. Because the Company was unable to assign value to the compounds at the time the agreement was executed and the $6.0 million was received from R-Tech, the full $6.0 million remained deferred at the abandonment of RUG-015.

	The abandonment of RUG-015 changed the amortization period of the $6.0 million deferred revenue to the commercialization period of AMITIZA, which began in April 2006. The Company has recognized revenue of $419,000 for the years ended December 31, 2013, 2012 and 2011, which is recorded as contract revenue. During the years ended December 31, 2013, 2012 and 2011, the Company purchased from R-Tech approximately $827,000, $1.4 million, and $72,000, respectively, of clinical supplies under the terms of this agreement. Commercial supplies of AMITIZA in the United States are subject to a three-party agreement among the Company, R-Tech and Takeda and are not reflected in the Company’s financial statements.

	On June 24, 2005, the Company entered into a 20-year exclusive manufacturing and supply agreement with R-Tech to manufacture and supply lubiprostone for clinical and commercial supplies within Europe. The Company amended this agreement in 2013 to reduce the per-capsule cost of the supply of lubiprostone. In consideration of the exclusive rights, R-Tech paid the Company $2.0 million prior to the execution of the agreement on March 31, 2005. Management has determined that the amount should be deferred until such time as the commercial benefit to R-Tech can be realized. As lubiprostone became available in the United Kingdom beginning in the fourth quarter of 2013, the $2.0 million deferral has been recorded as both current and non-current deferred revenue as of December 31, 2013, and as non-current deferred revenue as of December 31, 2012. In 2014 the Company will begin to ratably recognize this deferred revenue into income. During the years ended December 31, 2013, 2012 and 2011, the Company purchased approximately zero, $124,000 and $125,000, respectively, of commercial supplies of lubiprostone from R-Tech in anticipation of a commercial launch in Europe.

	On September 7, 2006, the Company’s Board approved an agreement which amends the exclusive manufacturing agreement with R-Tech. This agreement allows the Company to elect a back-up supplier for the supply of drug substance and drug product. In addition, the agreement provides that R-Tech shall maintain at least a six-month inventory of drug substance and at least a six-month inventory of intermediate drug product. The Company had no clinical supply purchases from a back-up supplier in 2013, 2012 or 2011.

	On October 4, 2006, the Company entered into a two-year exclusive clinical manufacturing and supply agreement with R-Tech for two of its drug compounds, cobiprostone and ion channel activators. Under the terms of this agreement, R-Tech agreed to manufacture and supply the necessary drug substance and drug product for the purpose of clinical development. Pricing for clinical supplies will be determined on a batch-by-batch basis and shall not exceed a certain mark-up percentage. Unless this agreement is terminated by mutual written consent within 90 days of expiration, it will automatically renew for additional two year terms. There were no clinical supplies purchased under the terms of this agreement during the years ended December 31, 2013, 2012 and 2011.

	In February 2009, the Company entered into an exclusive manufacturing and supply agreement with R-Tech under which the Company granted R-Tech the exclusive right to manufacture and supply lubiprostone to meet its commercial and clinical requirements in Asia, Australia and New Zealand. In consideration, R-Tech made an upfront payment of $250,000 and $500,000 in milestone payments for the regulatory approval of lubiprostone in Japan. R-Tech is obligated to pay $250,000 upon the commercial launch in Japan, which occurred in November 2012. The $250,000 will be amortized over the life of the agreement. In addition, R-Tech is required to maintain at least a six-month supply of lubiprostone and a three-month supply of the active ingredient used in manufacturing lubiprostone as a backup inventory. During the years ended December 31, 2013, 2012 and 2011, the Company purchased approximately $14.9 million, $3.1 million and $166,000, respectively, of commercial supplies of lubiprostone from R-Tech under this agreement. During the years ended December 31, 2013 and 2012, the Company purchased approximately $673,000 and $10,000, respectively, of clinical supplies from R-Tech under this agreement. There were no such clinical supplies purchases in 2011 from R-Tech under this agreement.

	The Company has also made purchases for other research and development services during the years ended December 31, 2013, 2012, and 2011 of approximately $194,000, $466,000 and $104,000, respectively.

	In 2009 and 2011, the Company entered into two agreements with R-Tech to license rights to RESCULA globally except the R-Tech Territory. Under the terms of the agreements, the Company holds the exclusive rights to commercialize RESCULA for its approved indication and any new indication developed by the Company, and has the right of first refusal to commercialize any additional indications for which unoprostone isopropyl is developed by R-Tech. The Company is solely responsible for the development, regulatory, and commercialization activities and expenses for RESCULA, and R-Tech is exclusively responsible for the supply of RESCULA to the Company. The terms of these agreements are described in Note 6 above.

	The Company recorded the following expenses under all of its agreements with R-Tech:

		Year Ended December 31,
	(In thousands)	2013		2012		2011
	Clinical supplies	$	827	$	1,450	$	72
	Other research and development services		194		466		104
	Commercial supplies		14,902		3,288		155
		$	15,923	$	5,204	$	331

		Year Ended December 31,
	(In thousands)	2013		2012
	Deferred revenue, current	$	477	$	479
	Deferred revenue, non-current		4,925		5,386
		$	5,402	$	5,865

	In March 2012, R-Tech advised the Company that it would relocate its manufacturing facility for unoprostone isopropyl in October 2012, and would not be able to manufacture and supply unoprostone isopropyl for up to 18 months. R-Tech has decided to contract with NittoMedic in Japan for the manufacture of unoprostone isopropyl but NittoMedic’s facility needed to be inspected by the FDA before it can manufacture unoprostone isopropyl. In light of this change in facility, the Company placed an order of $5.6 million of unoprostone isopropyl to cover this supply period based on the Company’s forecasts for the launch of RESCULA in the United States. R-Tech delivered $5.6 million of that order to the Company in the first and second quarters of 2013. This inventory was substantially written-off as discussed in Note 2 above. The Company filed a supplemental new drug application, or sNDA, in July 2013 for the new facility. The NittoMedic facility was inspected by the FDA in the fourth quarter of 2013. As a result of the inspection, FDA issued deficiencies to NittoMedic and a complete response letter to us with regard to the drug master file. NittoMedic has responded to the deficiencies and we have asked the FDA to proceed with its review of the sNDA, which it has indicated it will do so. The Company is awaiting the decision by the FDA.

	In addition, R-Tech has a 30-year lease with Ueno Fine Chemicals Industry, LTD., or Ueno Fine Chemical, for the land upon which R-Tech’s manufacturing facility that produces lubiprostone is located. There are approximately 20 years remaining on the lease and R-Tech’s manufacturing facility is on the campus of Ueno Fine Chemical. R-Tech and Ueno Fine Chemical are in litigation in Japan over the terms of the lease including whether or not the lease should be terminated. However, based on information from R-Tech, the Company does not believe that the dispute will adversely affect the supply of lubiprostone.

	Drs. Ryuji Ueno and Sachiko Kuno are married to each other and, directly or indirectly, own the majority of the stock of R-Tech. Drs. Ueno and Kuno are also controlling stockholders of the Company. Dr. Ueno was the Company’s Chief Executive Officer and Chairman of the Board and member through March 3, 2014, and is our Chief Scientific Officer, Co-Founder and Chairman Emeritus. On March 31, 2014, Dr. Ueno will step down as Chief Scientific Officer and will become Scientific Advisor.

Note_11_Notes_Payable

Note 11 - Notes Payable	12 Months Ended
Note 11 - Notes Payable	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	11. Notes Payable

	In November 2010, the Company entered into a ¥1,000,000,000, approximating $11.6 million as of the closing date, secured term loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd, or the Bank. The loan agreement provides for the extension of credit for the period of one year that can be renewed annually upon the agreement of the Company and the Bank. The loan was renewed in November 2013. Borrowings may be used to finance research and development activities, for working capital needs and for the general corporate purposes of the Company. The loan bears annual interest based on the three-month Tokyo Interbank Offer Rate, or TIBOR, plus 1% and is reset quarterly. The interest rate at December 31, 2013 was 1.22%. The outstanding loan balances included in the accompanying Consolidated Balance Sheets were $9.5 million and $11.6 million as of December 31, 2013 and 2012, respectively. The loan agreement includes representations, covenants, and events of default customary for financing transactions of this type. Additionally, the Company agreed to maintain an amount of collateral that would not fall below 90.0% of the initial balance throughout the term of the loan. The Company deposited $14.9 million with the Bank and the deposit bears annual interest of 0.25%, which is recorded as restricted cash, current in the accompanying Consolidated Balance Sheets as of December 31, 2013 and 2012. Due to the short-term maturity of the facility, the Company estimated that the carrying value approximated the fair value at December 31, 2013 and 2012.

	In March 2013, the Company entered into a ¥1,000,000,000, approximating $10.6 million as of the closing date, secured term loan agreement with the Mizuho Bank. The loan agreement provides for the extension of credit for the period of one year, which can be renewed annually upon the agreement of the Company and the Mizuho Bank. Borrowings may be used to finance research and development activities, for working capital needs and for the general corporate purposes of the Company. The loan bears annual interest based on the three-month TIBOR plus 0.25% and is reset quarterly. The interest rate at December 31, 2013 was 0.47%. The outstanding loan balance included in the accompanying Condensed Consolidated Balance Sheets was $9.5 million as of December 31, 2013. The loan agreement includes representations, covenants, and events of default customary for financing transactions of this type. Additionally, the Company agreed to maintain an amount of collateral that would not fall below 100% of the initial balance throughout the term of the loan. The Company deposited $11.0 million with the Mizuho Bank and the deposit bears annual interest of 0.30%, which is recorded as restricted cash, current in the accompanying Condensed Consolidated Balance Sheets as of December 31, 2013. Due to the short-term maturity of the agreement, the Company estimated that the carrying value approximated the fair value at December 31, 2013.

	Subordinated Unsecured Promissory Notes

	In connection with the SAG acquisition in 2010, the Company issued a subordinated unsecured promissory note, or notes, to the Ueno Trust and Kuno Trust. Each of the notes was issued with an initial principal balance of approximately $25.9 million, or approximately $51.9 million in the aggregate. The interest rate for the notes is equal to the per annum rate of interest determined on the basis of the sum of London Interbank Offered Rate, or LIBOR, plus 4.0%, and will be reset every six months on December 1st and June 1st of each year. The interest rate beginning December 1, 2013 is 4.3%.

	The notes provide for a semi-annual repayment schedule of interest and principal over a seven-year period on each June 1st and December 1st, provided that, through December 1, 2012, all accrued and unpaid interest was not paid in cash, but rather added to the principal balance of the notes. Interest paid-in-kind was nil, $2.2 million and $2.3 million for the three years ended December 31, 2013, 2012 and 2011, respectively.

	The notes can be prepaid at any time without penalty. In addition, the notes provide for a mandatory prepayment (i) in full in the event of an acquisition by an unaffiliated third party in an all-cash acquisition of all of the issued and outstanding shares of capital stock of the Company or (ii) either in full or in part in certain change of control transactions involving the Company where an unaffiliated third party acquires a majority of the Company’s voting stock.

	Due to changes in LIBOR rates the Company has estimated the fair value of the notes payable and this is shown in the table below.

	Notes payable at their carrying amount and fair value consist of the following:

		Fair Value		Carrying Value
		December 31,		Year Ended December 31,
	(In thousands)	2013		2013		2012
	Loan agreements	$	19,008	$	19,008	$	11,600
	Promissory notes, Sellers of SAG		34,889		33,712		41,251
		$	53,897	$	52,720	$	52,851

	Notes payable, current			$	26,892	$	19,129
	Notes payable, non-current				25,828		33,722
				$	52,720	$	52,851

	The Company's debt is subject to the fair value disclosure requirements as discussed in Note 4 above, and is classified as a Level 2 security.

Note_12_Collaboration_and_Lice

Note 12 - Collaboration and License Agreements	12 Months Ended
Note 12 - Collaboration and License Agreements	Dec. 31, 2013
Collaborative And License Arrangement Disclosure [Abstract]	'
Collaborative And License Arrangement Disclosure [Text Block]	'
	12. Collaboration and License Agreements

	Abbott license and commercialization and supply agreement

	In February 2009, the Company entered into the Abbott Agreement to develop and commercialize lubiprostone for the treatment of CIC in Japan. Additionally, the agreement grants Abbott the right of exclusive negotiation to any additional indications for which lubiprostone is developed in Japan under all relevant patents, know-how and trademarks. Under the terms of the Abbott Agreement, payments to the Company include a non-refundable upfront payment and non-refundable development and commercial milestone payments based on achieving specified development, regulatory and sales goals.

	The collaboration efforts under the agreement are governed by two committees consisting of an equal number of representatives from both parties. The joint commercialization and steering committee oversees commercialization-related activities and resolves any conflicts arising from a joint development committee, which oversees the development-related activities in Japan.

	The Company is required to fund and complete all the development work including additional clinical studies required to obtain regulatory approval for the treatment of CIC in Japan. The Company completed all development activities in the fourth quarter of 2012. The Company owns all the rights covered under the regulatory filings.

	Abbott is required to fund and undertake all commercialization efforts including pre-launch and post-launch marketing, promotion and distribution. Abbott is required to maintain the number of sales staff and the estimated level of annual net sales based on the commercialization plan to be developed and approved by the joint commercialization and steering committee described above.

	As of December 31, 2013, the Company has received a total of $37.5 million in up-front and development milestone payments under the Abbott Agreement, consisting of a $15.0 million development milestone payment received in December 2012 for the first commercial sale of AMITIZA, as well as $10.0 million and $12.5 million in up-front and development milestone payments, respectively, received in 2009. Under the Abbott Agreement, the Company could receive additional milestone payments based on achieving other specified development and commercialization goals although there can be no assurance that the Company will receive any such payments.

	The following table summarizes the cash streams and related revenue recognized or deferred under the Abbott Agreement for the year ended December 31, 2013:

			Cash		Revenue Recognized for the						Accounts		Foreign			Amount
			Received		Year Ended December 31,						Receivable for		Currency			Deferred at
			Through								the Year Ended					December 31,
			December 31,								December 31,
	(In thousands)		2013		Through 2011		2012		2013		2013		Effects			2013
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees		$	846	$	137	$	52	$	52	$	-	$	50		$	555

	Research and development revenue:
	Up-front payment - remainder		$	9,154	$	9,103	$	199	$	-	$	-	$	(148	)	$	-
	Development milestone payment			27,500		12,598		15,157		-		-		(255	)		-
	Total		$	36,654	$	21,701	$	15,356	$	-	$	-	$	(403	)	$	-


	Product sales revenue:		$	19,017	$	-	$	5,023	$	15,807	$	2,076	$	263		$	-

	Takeda collaboration and license agreement

	In October 2004, the Company entered into the Takeda Agreement to exclusively co-develop, commercialize and sell products that contain lubiprostone for gastroenterology indications in the United States and Canada. On February 1, 2006, the Company entered into the Supplemental Takeda Agreement, which supplemented the responsibilities of both the Company and Takeda for the co-promotion of AMITIZA and clarified the responsibilities and funding arrangements for other marketing services to be performed by both parties. Payments to the Company under these agreements include a non-refundable upfront payment, non-refundable development and commercial milestone payments, reimbursement of certain development and co-promotion costs and product royalties. The provision in the Supplemental Takeda Agreement concerning the co-promotion reimbursement for the Company’s sales force expired in May 2011 and the reimbursement terms of the Takeda Agreement apply.

	The Company has received a total of $160.0 million in upfront and development milestone payments through December 31, 2013 under the Takeda Agreement, including a $10.0 million development milestone received in the second quarter of 2013 for the first commercial sale of AMITIZA for OIC. Subject to development and acceptance of future indications, the Company is potentially entitled to receive additional development milestone and commercial milestone payments under the Takeda Agreement, although there can be no assurance that the Company will receive any such payments.

	The following table summarizes the cash streams and related revenue recognized or deferred under the Takeda Agreement for the year ended December 31, 2013:

			Cash		Revenue Recognized for the						Accounts		Amount
			Received		Year Ended December 31,						Receivable for		Deferred at
			Through								the Year Ended		December 31,
			December 31,								December 31,
	(In thousands)		2013		Through 2011		2012		2013		2013 (1)		2013
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees		$	2,375	$	1,052	$	147	$	147	$	-	$	1,029

	Research and development revenue:
	Up-front payment - remainder		$	17,624	$	17,624	$	-	$	-	$	-	$	-
	Development milestones			140,000		130,000		-		10,000		-		-
	Reimbursement of research and development expenses			114,670		100,262		6,189		10,354		2,554		419
	Total		$	272,294	$	247,886	$	6,189	$	20,354	$	2,554	$	419

	Product royalty revenue		$	276,598	$	188,631	$	50,696	$	52,100	$	14,829	$	-

	Co-promotion revenue		$	29,453	$	25,816	$	3,576	$	61	$	-	$	-

	(1) Includes billed and unbilled accounts receivable.

	Upon execution of the Takeda Agreement, the Company was required to complete several deliverables, which Takeda was responsible to fund. The following are the required deliverables of the Company, along with the related contractual cash flows from Takeda and the associated obligations and performance period of the Company relating to research and development revenue:

	·	Upon receipt of the $20.0 million upfront payment, the Company deferred approximately $2.4 million to be recognized using the time-based model over the performance period of the participation in various joint committee meetings. The Company expects its participation on all committees to continue throughout the term of the Takeda Agreement. During each of the years ended December 31, 2013, 2012 and 2011, the Company recognized approximately $147,000 of this deferred amount as collaboration revenue on the Consolidated Statements of Operations and Comprehensive Income (Loss). The related deferred revenue as of December 31, 2013 and 2012 was approximately $1.0 million and $1.2 million, respectively.

·	The Company granted Takeda an exclusive license of lubiprostone to co-develop, commercialize, and sell products for gastroenterology indications in the U.S. and Canada. There are no defined contractual cash flows within the Takeda Agreement for the grant of this license, but the Company did receive a non-refundable upfront payment of $20.0 million upon executing the Takeda Agreement. The license was granted to Takeda on October 29, 2004 and will expire when the Takeda Agreement expires or is terminated. After the commercial launch in 2006, Takeda has paid the Company pre-determined royalties on net revenues on a quarterly basis for the products sold by Takeda during the term of the Takeda Agreement. The level of royalties is tiered based on the net sales recognized by Takeda. The Company has recorded product royalty revenue of approximately $52.1 million, $50.7 million and $41.5 million for the years ended December 31, 2013, 2012 and 2011, respectively. This revenue is recorded as product royalty revenue in the Consolidated Statements of Operations and Comprehensive Income (Loss).

·	The Company has provided development work necessary for an NDA submission to the FDA for the treatment of CIC and IBS-C indications. Takeda funded the initial $30.0 million of development costs, the Company was obligated to fund the first $20.0 million in excess of the initial $30.0 million funded by Takeda and the two parties are to equally share any required development costs in excess of $50.0 million. Although there was no defined performance period for this development work, the period to perform the work would not exceed the term of the Takeda Agreement. In January 2006, the Company received approval for its NDA for AMITIZA to treat CIC and completed and submitted the supplemental NDA for IBS-C to the FDA in June 2007.

The Company initially deferred the residual amount of the $20.0 million upfront payment totaling approximately $17.6 million, development milestone payments received totaling $50.0 million, and reimbursement of the initial $30.0 million of research and development costs for the development of AMITIZA for CIC and IBS-C indications. These deferred amounts were applied towards the unit of accounting that combines the participation in the joint development committee and the development of CIC and IBS-C and was recognized over the performance period of developing the CIC and IBS-C NDA submissions. The Company completed the development of the CIC and IBS-C in June 2007 and filed a sNDA for IBS-C. This was the culmination of the performance period. In June 2007, the Company also recognized as revenue, in full, $30.0 million from Takeda upon the filing of the sNDA for AMITIZA to treat IBS-C. The Company received a $50.0 million development milestone from Takeda as a result of the FDA’s approval on April 29, 2008 of the sNDA for IBS-C in women aged 18 years and older and recognized the payment as research and development revenue during the year ended December 31, 2008.

During 2006, the joint commercialization committee granted approval for the Company and Takeda to begin three new studies related to funding arrangements discussed in both the Takeda Agreement and the Supplemental Takeda Agreement. The following are the three additional deliverables of the Company, along with the related contractual cash flows from Takeda and the associated obligations and performance period of the Company, when the three studies were agreed upon:

·	The Company is obligated to perform studies in connection with changes to labeling for CIC. Takeda is obligated to fund 70% of the labeling studies and the Company is obligated to fund the remaining 30%. There is no defined performance period, but the performance period will not exceed the term of the Takeda Agreement.

·	The Company is obligated to perform studies for the development of an additional indication for OIC. Takeda is obligated to fund all development work up to a maximum aggregate of $50.0 million for each additional indication and $20.0 million for each new formulation. If development costs exceed these amounts, Takeda and the Company shall equally share such excess costs. There is no defined performance period, but the performance period will not exceed the term of the Takeda Agreement. The Company decided to conduct one additional phase 3 efficacy study in order to submit a sNDA for the OBD indication. In February 2012, the Company announced that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of OBD in patients with chronic, non-cancer pain, excluding those taking methadone.

·	The Company is obligated to perform all development work necessary for phase 4 studies, for which Takeda is obligated to fund all development work. There is no defined performance period, but the performance period will not exceed the term of the Supplemental Takeda Agreement.

The Company has assessed these required deliverables to determine which deliverables are considered separate units of accounting. As a result of the Company and Takeda agreeing to perform and fund these studies simultaneously, the Company determined that there is no objective and reliable evidence to determine the fair value for each of the studies. Accordingly, the Company has combined these three required deliverables as a single unit of accounting. All cash payments from Takeda related to these three deliverables are deferred upon receipt and recognized over the estimated performance period to complete the three studies using the time-based model. During the years ended December 31, 2013, 2012 and 2011, the Company recognized approximately $10.4 million, $4.4 million and $8.0 million related to these three deliverables as research and development revenue in the Consolidated Statements of Operations and Comprehensive Income (Loss), respectively.

In 2011, the Joint Commercialization Committee (JCC) granted approval to begin studies for a liquid formulation. In addition, in 2012, the JCC granted approval for studies for a pediatric dosage. These additional deliverables are considered separate units of accounting and the Company recognizes revenue from Takeda reimbursements for these deliverables when earned.

On February 1, 2006, the Company entered into the Supplemental Takeda Agreement, which amended the responsibilities of both the Company and Takeda for the co-promotion of AMITIZA and clarified the responsibilities and funding arrangements for other marketing services to be performed by both parties.

The reimbursement of co-promotion costs under the Supplemental Takeda Agreement expired on May 31, 2011. Co-promotion costs after May 31, 2011 were reimbursed under the Takeda Agreement. The previous reimbursement terms of the Supplemental Takeda Agreement were based on a per diem amount by the number of our sales representatives in the field promoting AMITIZA. After May 2011, the Company was reimbursed on actual details presented to health care prescribers. The Company has recognized approximately $61,000, $3.6 million and $3.4 million of revenues for the years ended December 31, 2013, 2012 and 2011, respectively, reflecting these co-promotion reimbursements, which is recorded as co-promotion revenue in the Consolidated Statements of Operations and Comprehensive Income (Loss).

The Company views the deliverables under the Supplemental Takeda Agreement as economically independent of those in the Takeda Agreement.

The Company has assessed these required deliverables to determine which deliverables are considered separate units of accounting. The Company determined that its sales force and miscellaneous marketing activities are treated as separate units of accounting. The Company is recognizing the cost reimbursements received for these deliverables as co-promotion revenues when services are performed and the reimbursement payments are due under the Supplemental Takeda Agreement.

Numab AG

In September 2011, the Company entered into a Loan Guarantee and Development Agreement, or the Numab Agreement, with Numab. Until September 2013, Numab was considered a related party as a result of an ownership interest in Numab by one of the Company’s former executive officers, who resigned in September 2013. Under the terms of the Numab Agreement, the Company would provide Numab with up to CHF 5.0 million as collateral and would serve as guarantor for a loan to Numab from a third party, Zurcher Kantonalbank. Following the payment of the first success fee during the first quarter of 2013, this amount was reduced to CHF 2.2 million, or approximately $2.5 million as of December 31, 2013.

As of December 31, 2013, the collateral of CHF 2.2 million has been deposited by the Company and Numab has utilized CHF 2.0 million of its loan facility, or approximately $2.2 million. During 2012, the Company considered it probable that the success criteria for the first target would be met and made full provision for the success fee. This fee was paid during the first quarter of 2013. In the first quarter of 2013, the Company decided to no longer pursue further development of the target. In October 2013, Numab and the Company entered into a termination arrangement which may result in continued development by Numab. After successful development by Numab and an agreement with a third party investor, Numab and the Company will enter into a license agreement on commercially reasonable terms. At December 31, 2013 and 2012, the Company has a recorded liability of $663,000 and nil, respectively, in collateral callable to meet a potential loan default by Numab.

Note_13_Stockholders_Equity

Note 13 - Stockholders' Equity

12 Months Ended

Dec. 31, 2013

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

13. Stockholders’ Equity

Capital Structure

On August 30, 2012, the Company announced that its majority stockholder and only holder of its class B common stock, S&R Technology Holdings, LLC, or S&R, had converted effective as of August 29, 2012, all of its 26,191,050 issued and outstanding shares of the Company’s class B common stock into shares of the Company’s class A common stock. S&R held all of the Company’s class B common stock. Class B common stock holders were entitled to ten votes per share while class A common stock holders were entitled to one vote per share. The Company’s Articles of Incorporation permit the holder of class B common stock to convert the shares of class B common stock into shares of class A common stock at any time and on a one-for-one basis. As a result of the conversion, there is now only a single class of common stock, class A common stock, outstanding, totaling 43,998,430 shares as of March 3, 2014, each of which is entitled to one vote per share.

Cantor Sales Agreement

On January 11, 2013, the Company entered into a sales agreement with Cantor Fitzgerald & Co., or the Cantor Sales Agreement, which enables the Company to offer and sell shares of the Company’s class A common stock with an aggregate sales price of up to $20.0 million, from time to time through Cantor Fitzgerald & Co. as our sales agent. Sales of class A common stock under the Cantor Sales Agreement are made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Cantor Fitzgerald & Co. is entitled to receive a commission rate of 3.0% of gross sales in connection with the sale of the Company’s class A common stock sold on the Company’s behalf. From November 22, 2013 through December 31, 2013, the Company had sold through the Cantor Sales Agreement an aggregate of 749,383 shares of the Company's class A common stock, and received gross proceeds of approximately $5.3 million, before deducting issuance expenses. The Company does not make repurchases under the stock repurchase program when it is making at-the-market equity offerings.

Treasury Stock

On December 11, 2008, the Company announced a stock repurchase program under which the Company is authorized to purchase up to $10.0 million of its class A common stock from time to time in open-market transactions. On September 8, 2011, the Company’s Board authorized the repurchase of up to an aggregate of $2.0 million of the Company’s class A common stock out of the $10.0 million authorized by the Board on December 9, 2008. On November 2, 2012, the Board authorized the increase of such amount of repurchase to up to an aggregate of $5.0 million. In 2013 and 2012, the Company repurchased 67,762 shares and 270,043 shares of its class A common stock under this program at a cost of $336,000 and $1.3 million, respectively. All shares of class A common stock purchased in 2013 were purchased in January, February and March. In 2012 all shares were purchased in August, September, October, November and December. These shares are not retired and are recorded at cost.

Stock Option Plans

On February 15, 2001, the Company adopted the 2001 Stock Incentive Plan, or the 2001 Incentive Plan, in order to provide common stock incentives to certain eligible employees, officers and directors, consultants and advisors of the Company. The Company’s Board administers the 2001 Incentive Plan and has sole discretion to grant options. On September 1, 2003, the Board amended the 2001 Incentive Plan to allow for a maximum of 8,500,000 shares of class A common stock to be issued under all awards, including incentive stock options under the 2001 Incentive Plan. In 2006, the Board determined no further options would be granted under this plan.

In August 2005, the Board granted 510,000 stock options to non-employees under the 2001 Incentive Plan. These non-employee stock options vested immediately and have a weighted average exercise price per share of $5.85. At December 31, 2013 and 2012, there were 410,000 and 450,000 options outstanding and exercisable with a remaining contractual life of 1.33 and 2.33 years, respectively.

On June 5, 2006, the Board approved a 2006 Stock Incentive Plan, or the 2006 Incentive Plan, which has been amended and restated, and reserved 8,500,000 shares of class A common stock for issuance under this plan. At December 31, 2013, a total of 5,986,937 shares were available for future grants under this plan. Option awards under the 2006 Incentive Plan are generally granted with an exercise price equal to the closing market price of the Company’s stock on the date of grant. The options generally vest over four years and have a ten-year contractual term.

On October 18, 2007, the Board approved an amendment to the 2006 Incentive Plan. The 2006 Incentive Plan includes an “evergreen” provision by which the number of shares of the Company’s class A common stock available for issuance under the 2006 Incentive Plan increases automatically on the first day of each calendar year by a number equal to 5.0% of the aggregate number of shares of the Company’s class A common stock and class B common stock outstanding on such date, or such lesser number as the Board of Directors may determine. The 2006 Incentive Plan will provide that the number of shares of class A common stock included in each annual increase will be 500,000, or such lesser number as the Board may determine. The Board determined that the amount of the increase in the shares available for issuance under the 2006 Incentive Plan as of January 1, 2009, 2010, 2011, 2012 and 2013 pursuant to the “evergreen” provision, would be zero.

On October 7, 2009, the Board adopted a new compensation program under the 2006 Incentive Plan for its non-employee directors, and approved a new form of stock option agreement to be used for future stock option awards to non-employee directors. According to the plan, the independent directors will receive an annual grant of 20,000 stock options on the date of each Annual Meeting of Stockholders. Additionally, the directors received an initial grant of 30,000 stock options upon the adoption of the plan.

On May 2, 2011, the Board amended the 2006 Incentive Plan for its non-employee directors, to increase the approved annual stock option grants to non-employee directors to 30,000 stock options on the date of each Annual Meeting of Stockholders. Such grants would consist of 60.0% service based options, and 40.0% market condition based options.

A summary of the employee stock option activity for the year ended December 31, 2013 under the Company’s 2001 Incentive Plan is presented below.

Weighted

Aggregate

Average

Intrinsic Value

Exercise

Remaining

Price Per

Contractual

Term (Years)

Options outstanding, December 31, 2012

156,400

Options expired

(10,200

)

Options outstanding, December 31, 2013

146,200

2.34

Options exercisable, December 31, 2013

146,200

2.34

A summary of the employee stock option activity for the year ended December 31, 2013 under the Company’s 2006 Incentive Plan is presented below:

Weighted

Aggregate

Average

Intrinsic Value

Exercise

Remaining

Price Per

Contractual

Term (Years)

Options outstanding, December 31, 2012

3,251,493

4.83

Options granted

204,250

7.36

Options exercised

(557,836

)

4.43

Options forfeited

(334,879

)

5.36

Options expired

(49,965

)

6.61

Options outstanding, December 31, 2013

2,513,063

5.03

7.34

11,346,066

Options exercisable, December 31, 2013

1,143,912

5.41

6.97

4,919,233

A summary of the non-employee stock option activity for the year ended December 31, 2013 under the Company’s 2001 Stock Incentive Plan is presented below:

Weighted

Aggregate

Average

Intrinsic Value

Exercise

Remaining

Price Per

Contractual

Term (Years)

Options outstanding, December 31, 2012

450,000

5.85

Options exercised

(40,000

)

5.85

Options outstanding, December 31, 2013

410,000

5.85

1.31

1,455,500

Options exercisable, December 31, 2013

410,000

5.85

1.31

1,455,500

During the year ended December 31, 2011, the Company made a grant of time-based and market condition options to all eligible employees and independent directors under its 2006 Incentive Plan. The aggregate options totaled 2,572,860 shares of the Company’s class A common stock, consisting of 873,352 shares of time-based options and 1,699,508 shares of market condition options. The market condition options (a) vest in certain percentages based on the attainment of specific stock price targets over a 30-day trading period so long as the individual is in continuous service with the Company on each such date, (b) have an exercise price equal to the closing price of the Company's class A common stock on the NASDAQ Global Market on the date of grant, and (c) must vest within a term of four years from such date. These options must be exercised within a term of ten years from the date of grant. The percentages and target prices are: 40.0% at $8.00 per share, 40.0% at $12.00 per share and 20.0% at $16.00 per share. The Company determined that the market condition options should be classified as equity instruments, and selected, in accordance with GAAP, a lattice option-pricing model to estimate the fair value of those options. A lattice option-pricing model produces an estimated fair value of the option based on the assumed changes in the price of the underlying share over successive periods of time. No market condition options were granted during 2013 or 2012. The time-based stock options (a) vest in equal annual installments over the four-year period commencing on the first anniversary of the date of grant so long as the individual is in continuous service with the Company on each such date and (b) have an exercise price equal to the closing price of the Company's class A common stock on the NASDAQ Global Market on the date of grant. These options must be exercised within a term of ten years from such date.

The weighted average grant date fair value of options granted during the years ended December 31, 2013, 2012 and 2011 were $7.36, $6.30 and $1.81, respectively. As of December 31, 2013, approximately $1.1 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested awards are expected to be recognized over a weighted average period of 1.65 years. When an option is exercised, the Company issues a new share of class A common stock.

Employee Stock Purchase Plan

On June 5, 2006, the Board approved a 2006 Employee Stock Purchase Plan, or ESPP, and reserved 4,250,000 shares of class A common stock for issuance under the ESPP. As of December 31, 2011, the Board has approved 500,000 shares of class A common stock for the ESPP. The ESPP is non-compensatory and is intended to qualify as an Employee Stock Purchase Plan as defined in Section 423 of the Internal Revenue Code of 1986. Under this plan, eligible employees may purchase common stock through payroll deductions of up to 10.0% of compensation during the plan period. The purchase price per share is 95.0% of market price at the end of each plan period, which is generally three months. A total of 3,625 and 3,550 shares of common stock were purchased under the ESPP during the years ended December 31, 2013 and 2012, respectively. The Company received approximately $24,000, $20,000 and $13,000 upon purchase of shares under the ESPP for the years ended December 31, 2013, 2012 and 2011, respectively.

Tax Benefits

As of December 31, 2013, the balance of the Company's additional paid-in capital pool related to tax windfall benefits from the stock option exercises was $213,000.

The Company applies a with-and-without approach in determining its intra-period allocation of tax expense or benefit attributable to stock based compensation deductions. Since the Company does not have any net operating loss carry-forwards in the U.S., the tax benefit reduces income taxes payable in the current year and is therefore recorded to additional paid-in-capital.

Note_14_Income_Taxes

Note 14 - Income Taxes	12 Months Ended
Note 14 - Income Taxes	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	14. Income Taxes

	Income (loss) before income taxes is as follows:

			Year Ending December 31,
			2013				2012				2011
	U.S.		$	9,175			$	8,580			$	(9,670	)
	Foreign			1,172				(828	)			(12,244	)
			$	10,347			$	7,752			$	(21,914	)

	The provision (benefit) for income taxes consists of the following for the three years ended December 31:

			Year Ended December 31,
	(In thousands)		2013				2012				2011
	Current tax provision (benefit):
	U.S. Federal		$	5,198			$	1,431			$	(597	)
	U.S. State			1,008				658				(194	)
	Foreign			(582	)			51				550
	Total current tax provision (benefit)			5,624				2,140				(241	)

	Deferred provision (benefit):
	U.S. Federal			(1,783	)			1,248				(1,369	)
	U.S. State			(279	)			(193	)			385
	Foreign			366				(279	)			(3,383	)
	Total deferred provision (benefit)			(1,696	)			776				(4,367	)

	Total income tax provision (benefit)		$	3,928			$	2,916			$	(4,608	)

	Deferred tax assets (liabilities), net, consist of the following as of December 31:

			December 31,
			2013				2012
	(In thousands)
	Deferred tax assets:
	Foreign net operating loss carry-forwards		$	2,538			$	5,132
	State net operating loss carry-forwards			38				100
	Deferred revenue			2,143				2,431
	Accrued expenses			1,637				1,316
	Tax benefits on stock options			2,378				1,832
	Inventory			1,243				-
	Other			220				388
	Gross deferred tax assets			10,197				11,199

	Deferred tax liabilities:
	Property and equipment			(202	)			(272	)
	Intangibles			(7,070	)			(6,884	)
	Gross deferred tax liabilities			(7,272	)			(7,156	)

	Less: valuation allowance			(1,751	)			(4,142	)
	Net deferred tax assets (liabilities)		$	1,174			$	(99	)

	The provision (benefit) for income taxes vary from the income taxes provided based on the federal statutory rate as follows for the three years ended December 31:

			Year Ended December 31,
	(In thousands)		2013				2012				2011
	Federal tax provision (benefit)			35	%			34	%			34	%
	State taxes, net of federal tax benefit			5.2	%			7.5	%			0.4	%
	General business credits			0	%			-0.5	%			1.6	%
	Changes in valuation allowance			-22.3	%			-3.7	%			-3.7	%
	Nondeductible expenses			1.3	%			1.7	%			-0.2	%
	Stock based compensation			-2.9	%			12.7	%			-1.9	%
	Impact of intangible transfer			7.7	%			-18.6	%			-4.7	%
	Impact of uncertain tax positions			-0.1	%			-4.2	%			-0.2	%
Adjustment to deferred tax asset			11.8	%			-10.4	%			0.1	%
Impact of foreign operations			1.8	%			6.4	%			-4.6	%
Change in tax rates			0.6	%			12.4	%			-0.1	%
Changes in other tax matters			-0.1	%			0.3	%			0.4	%
			38	%			37.6	%			21.1	%

At December 31, 2013 and 2012, the Company had foreign net operating loss carry-forwards of $11.9 million and $21.0 million, respectively. Approximately $7.0 million of the foreign NOLs begin to expire in December 2019, and $4.9 million of the foreign NOLs do not expire. As of December 31, 2013 and 2012, the Company had no NOLs in the United States.

As of December 31, 2013 and 2012, the Company had a valuation allowance on its deferred tax assets of $1.8 million and $4.1 million, respectively. The net decrease in the valuation allowance of $2.4 million was due to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized, as well as the reversal of all deferred tax assets of Ambrent due to its anticipated liquidation in early 2014. Please refer to the income tax and deferred charge policy for further description of this intercompany transaction.

In September 2011, the Company internally transferred certain intellectual property and licenses from the Company’s subsidiaries, including the United States based subsidiary, to SAG. Since the transfer of these assets was to a related party, the recognition of a deferred tax asset by SAG is prohibited and the net tax effect of the transaction is deferred in consolidation. The tax liability generated from this transaction is offset by a deferred charge that is being amortized over ten years. Following the decision of the International Court of Arbitration of the International Chamber of Commerce on the Takeda Agreement in July 2012, the Company determined that the internal transfer of the intellectual property was only partially complete and is continuing to evaluate whether the United States rights related to AMITIZA will transfer to SAG in the future. This resulted in a reassessment of the deferred charge, deferred tax liability and the mix of profits and losses earned in each jurisdiction. For the year ended December 31, 2012, the Company recorded a benefit of approximately $1.9 million related to the partial reversal of the internal transfer and reduced the deferred charge and deferred tax liability by approximately, $23.8 million and $24.1 million respectively. As of December 31, 2013, the total deferred charge is $5.2 million after a net current year amortization expense of $673,000.

The valuation allowance at December 31, 2013 and 2012 relates to deferred tax assets in the foreign jurisdictions. A partial valuation allowance was maintained on the deferred tax assets of the Company’s subsidiary in Japan based on management’s estimate of the NOL carry-forwards that will expire unused. The Company will continue to evaluate its valuation allowance position in each jurisdiction on a regular basis. To the extent the Company determines that all or a portion of its valuation allowance is no longer necessary, the Company will recognize an income tax benefit in the period such determination is made for the reversal of the valuation allowance. Once the valuation allowance is eliminated in whole or in part, it will not be available to offset the Company’s future tax provision. As of December 31, 2013, the Company does not expect to reverse any of the valuation allowance in the next twelve months.

The Company has recorded a total income tax liability of approximately $679,000 and $1.1 million, including interest for uncertain tax positions as of December 31, 2013 and 2012, respectively. The Company expects to settle prior periods with state tax authorities; therefore, the amount of $42,000 expected to reverse within the next twelve months has been reflected as other current liabilities and the remaining $637,000 has been recorded as other liabilities in the accompanying Consolidated Balance Sheets. The amount represents the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Consolidated Financial Statements. The liability for uncertain tax positions as of December 31, 2013 and 2012 mainly pertains to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes, as well as uncertain tax positions related to related party interest in foreign jurisdictions.

A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows:

		Year Ended December 31,
		2013				2012				2011
Balance at January 1		$	979			$	1,226			$	1,245
Increases for tax positions taken during prior periods			4				207				22
Decreases in unrecognized tax benefits related to settlements with taxing authorities			(467	)			(536	)			(71	)
Increases for tax positions taken during current period			34				82				30
Balance at December 31		$	550			$	979			$	1,226

The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. During 2013, 2012 and 2011, the Company recorded approximately $22,000, $42,000 and $69,000, respectively, of interest related to uncertain tax positions. Other than the decrease related to the settlement of state income liabilities, no additional uncertain tax positions have been identified for which it is reasonably possible that the total amount of liability for unrecognized tax benefits will significantly increase or decrease within the next 12 months, except for recurring accruals on existing uncertain tax positions. In addition, future changes in the unrecognized tax benefits described above would have an impact on the effective tax rate.

Currently tax years 2010, 2011, 2012 and 2013 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed. The tax years 2009-2011 are currently under examination by the U.S. tax authorities. Management does not believe that the result of such examination will have a material impact on the financial statements.

Note_15_Segment_Reporting

Note 15 - Segment Reporting	12 Months Ended
Note 15 - Segment Reporting	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	15. Segment Reporting

	The Company has determined that it has three reportable segments based on the Company’s method of internal reporting, which disaggregates business by geographic location. These segments are the Americas, Europe and Asia. The Company evaluates the performance of these segments based on income (loss) from operations, as well as other factors, that depend on the development status of these geographies. Such measures include the progress of its research and development activities, collaboration and licensing efforts, commercialization activities, product sales and other factors. The reportable segments have historically derived their revenue from joint collaboration and strategic alliance agreements. Transactions between the segments consist primarily of loans and the provision of research and development services. Following is a summary of financial information by reportable geographic segment:

	(In thousands)		Americas				Europe				Asia				Consolidated
	Year Ended December 31, 2013
	Research and development revenue		$	20,354			$	-			$	-			$	20,354
	Product royalty revenue			52,100				-				-				52,100
	Product sales revenue			556				62				15,807				16,425
	Co-promotion revenue			61				-				-				61
	Contract and collaboration revenue			566				46				42				654
	Total revenues			73,637				108				15,849				89,594
	Cost of goods sold			3,588				15				8,799				12,402
	Research and development expenses			11,090				5,445				4,989				21,524
	Depreciation and amortization			736				716				36				1,488
	Other operating expenses			35,911				5,900				3,173				44,984
	Income (loss) from operations			22,312				(11,968	)			(1,148	)			9,196
	Interest income			112				11				1				124
	Interest expense			(1,427	)			(302	)			(165	)			(1,894	)
	Other non-operating expense, net			(14	)			(166	)			3,101				2,921
	Income (loss) before income taxes		$	20,983			$	(12,425	)		$	1,789			$	10,347
	Capital expenditures		$	40			$	105			$	23			$	168

	(In thousands)		Americas				Europe				Asia				Consolidated
	Year Ended December 31, 2012
	Research and development revenue		$	6,189			$	-			$	15,356			$	21,545
	Product royalty revenue			50,696				-				-				50,696
	Product sales revenue			-				14				5,023				5,037
	Co-promotion revenue			3,576				-				-				3,576
	Contract and collaboration revenue			565				16				52				633
	Total revenues			61,026				30				20,431				81,487
	Cost of goods sold			98				9				2,923				3,030
	Research and development expenses			7,809				9,571				3,912				21,292
	Depreciation and amortization			484				964				40				1,488
	Other operating expenses			41,410				2,993				2,957				47,360
	Income (loss) from operations			11,225				(13,507	)			10,599				8,317
	Interest income			161				16				2				179
	Interest expense			-				(2,183	)			(163	)			(2,346	)
	Other non-operating expense, net			77				(187	)			1,712				1,602
	Income (loss) before income taxes		$	11,463			$	(15,861	)		$	12,150			$	7,752
	Capital expenditures		$	401			$	3,470			$	-			$	3,871

	Year Ended December 31, 2011
	Research and development revenue		$	8,033			$	-			$	1,216			$	9,249
	Product royalty revenue			41,517				-				-				41,517
	Co-promotion revenue			3,378				-				-				3,378
	Contract and collaboration revenue			565				-				52				617
	Total revenues			53,493				-				1,268				54,761
	Research and development expenses			24,058				4,354				5,085				33,497
	Settlement for legal dispute			(11,100	)			-				-				(11,100	)
	Depreciation and amortization			791				474				43				1,308
	Other operating expenses			46,326				1,092				1,327				48,745
	Income (loss) from operations			(6,582	)			(5,920	)			(5,187	)			(17,689	)
	Interest income			240				6				3				249
	Interest expense			-				(2,288	)			(167	)			(2,455	)
	Other non-operating expense, net			(42	)			(1,884	)			(93	)			(2,019	)
	Income (loss) before income taxes		$	(6,384	)		$	(10,086	)		$	(5,444	)		$	(21,914	)
	Capital expenditures		$	145			$	6,006			$	133			$	6,284

	As of December 31, 2013
	Property and equipment, net		$	869			$	112			$	175			$	1,156
	Identifiable assets, net of intercompany loans and investments		$	95,350			$	23,843			$	17,780			$	136,973

As of December 31, 2012
Property and equipment, net		$	1,276			$	36			$	228			$	1,540
Identifiable assets, net of intercompany loans and investments		$	87,731			$	25,465			$	14,600			$	127,796

Note_16_Quarterly_Financial_Da

Note 16 - Quarterly Financial Data (Unaudited)	12 Months Ended
Note 16 - Quarterly Financial Data (Unaudited)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	16. Quarterly Financial Data (unaudited)

		2013 Quarters Ended
	(In thousands, except per share data)	31-Dec		30-Sep			30-Jun			31-Mar
	Total revenues	$	24,490	$	21,163		$	27,023		$	16,919
	Income (loss) from operations	$	2,679	$	(1,044	)	$	10,169		$	(2,608	)
	Net income (loss)	$	2,153	$	1,291		$	6,119		$	(3,145	)
	Net income (loss) per share:
	Basic	$	0.05	$	0.03		$	0.15		$	(0.08	)
	Diluted	$	0.05	$	0.03		$	0.14		$	(0.08	)

		2012 Quarters Ended
	(In thousands, except per share data)	31-Dec		30-Sep			30-Jun			31-Mar
	Total revenues	$	34,862	$	15,496		$	16,683		$	14,446
	Income (loss) from operations	$	12,966	$	(1,653	)	$	(2,674	)	$	(322	)
	Net income (loss)	$	13,532	$	(5,949	)	$	(819	)	$	(1,928	)
	Net income (loss) per share:
	Basic	$	0.33	$	(0.14	)	$	(0.02	)	$	(0.05	)
	Diluted	$	0.32	$	(0.14	)	$	(0.02	)	$	(0.05	)

	Net income (loss) per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share information may not equal annual net income (loss) per share.

Note_17_Subsequent_Events

Note 17 - Subsequent Events	12 Months Ended
Note 17 - Subsequent Events	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	17. Subsequent Events

	On February 10, 2014, the Company announced that Peter Greenleaf will join the Company as Chief Executive Officer, or CEO, and a member of the Board on March 3, 2014. Dr. Ryuji Ueno will step down as CEO and member and Chairman of the Board on March 3, 2014, and as Chief Scientific Officer on March 31, 2014. Dr. Daniel P. Getman will become Chairman of the Board on March 3, 2014.

	The dissolution of Ambrent Investments, S.à r.l., or Ambrent, which began in the fourth quarter of 2013, is expected to be completed in the first quarter of 2014. Any remaining assets or liabilities of Ambrent will be transferred to Sucampo LLC.

	On March 6, 2014, the Company was advised by Gayle R. Dolecek, P.D. that he will not stand for re-election as a member of the Board at the annual shareholder meeting on May 9, 2014, but will continue as a consultant of the Company under his existing consulting agreement. Dr. Dolecek's departure is not the result of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices. The Nominating and Corporate Governance Committee of the Board will begin a search to fill the vacancy created by Dr. Dolecek's departure.

	On March 7, 2014, MHRA notified the Company that the application for Type II variation to update the summary of product characteristics to include the additional therapeutic indication of the treatment of opioid-induced constipation and associated signs and symptoms in adults with chronic, non-cancer pain in the UK was not approved and we are considering the appropriate next steps with MHRA.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
Schedule II - Valuation and Qualifying Accounts	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	'
	Schedule II – Valuation and Qualifying Accounts

	(In thousands)		Balance at		Additions			Deductions				Balance at
			Beginning		Charged to							End of Year
			of Year		Costs and
					Expenses
	Allowance for doubtful accounts:
	2011		$	-	$	-		$	-			$	-
	2012		$	-	$	280	(a)	$	-			$	280
	2013		$	280	$	160	(a)	$	-			$	440
	Valuation allowance for deferred tax assets:
	2011		$	9,658	$	932	(b)	$	(6,123	)	(b)	$	4,467
	2012		$	4,467	$	1,073	(c)	$	(1,398	)	(c)	$	4,142
	2013		$	4,142	$	-		$	(2,391	)	(d)	$	1,751

	(a)	In 2013 and 2012, the increase in allowance for doubtful accounts is primarily associated with certain disputed Takeda invoices.

	(b)	In 2011, the net decrease in the valuation allowance of $5.2 million was due primarily to the recognition of gains in local tax jurisdictions on the transfer of certain intellectual property to SAG as well as the partial release of valuation allowances in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized.

	(c)	In 2012, the net decrease in valuation allowance of $325,000 was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized.

	(d)	In 2013, the net decrease in valuation allowance of $2.4 million was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized, as well as the reversal of all deferred tax assets of Ambrent for anticipated liquidation.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash

Investment, Policy [Policy Text Block]

Current and Non-Current Investments

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Certain Risks, Concentrations and Uncertainties

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Accounts Receivable and Unbilled Accounts Receivable

Royalty Recognition Policy [Policy Text Block]

Product Royalties Receivable

Product royalties receivable represent amounts due from Takeda for the Company’s royalties on sales of AMITIZA, which are based on reports obtained directly from Takeda.

Inventory, Policy [Policy Text Block]

Inventory

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment Evaluation for Long-lived Assets

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company’s revenues are derived primarily from product royalties, development milestone payments, clinical development activities and product sales.

Research and Development Revenue [Policy Text Block]

Research and Development Revenue

Contract revenue relates to development and consulting activities and is accounted for under the time-based model.

Product Royalty Revenue [Policy Text Block]

Product Royalty Revenue

Revenue Recognition, Sales of Goods [Policy Text Block]

Product Sales Revenue

Copromotion Revenue Policy Text Block

Co-promotion Revenue

Co-promotion revenue relates to a limited reimbursement of co-promotion costs based on details to healthcare prescribers.

Contract Revenue Policy Text Block [Policy Text Block]

Contract and Collaboration Revenue

Contract revenue relates to development and consulting activities and is accounted for under the time-based model.

Revenue Recognition, Deferred Revenue [Policy Text Block]

Deferred Revenue

Total deferred revenue consists of the following as of:

December 31,

(In thousands)

2013

2012

Deferred revenue, current

1,365

3,700

Deferred revenue, non-current

6,169

7,093

7,534

10,793

Deferred revenue to related parties, included in total deferred revenue:

Deferred revenue to related parties, current

477

479

Deferred revenue to related parties, non-current

4,925

5,386

Total

5,402

5,865

Cost of Sales, Policy [Policy Text Block]

Cost of Goods Sold

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses

Selling, General and Administrative Expenses, Policy [Policy Text Block]

General and Administrative Expenses

Selling and Marketing Expenses

Interest Income, Policy [Policy Text Block]

Interest Income

Interest income consists of interest earned on the Company’s cash and cash equivalents and current and non-current investments.

Accrued Research and Development Expenses, Policy [Policy Text Block]

Accrued Research and Development Expenses

Compensation Related Costs, Policy [Policy Text Block]

Employee Stock-Based Compensation

The assumptions used to estimate the fair value of stock options granted for the three years ended December 31, 2013 were as follows:

Year Ended December 31,

2013

2012

2011

Expected volatility

65%

75%

62%

64%

55%

64%

Risk-free interest rate

1.23%

1.40%

0.76%

1.60%

1.30%

3.30%

Expected term (in years)

5.5

6.25

5.5

6.25

2.1

6.25

Expected dividend yield

Expected Dividend Yield: The Company has not paid, and does not anticipate paying, any dividends in the foreseeable future.

Employee stock-based compensation expense recorded in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) for the three years ended December 31, 2013 was as follows:

Year Ended December 31,

(In thousands)

2013

2012

2011

Research and development expense

293

535

234

General and administrative expense

1,260

1,349

964

Selling and marketing expense

191

349

172

Total

1,744

2,233

1,370

Employee stock-based compensation expense per basic and diluted share of common stock

0.04

0.05

0.03

Income Tax, Policy [Policy Text Block]

Income Taxes

Income Tax Uncertainties, Policy [Policy Text Block]

Uncertain Tax Positions

Currently, tax years 2010, 2011, 2012 and 2013 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed.

Deferred Charges, Policy [Policy Text Block]

Deferred Charge

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency

Realized and unrealized foreign currency gains or losses on assets and liabilities denominated in a currency other than the functional currency are included in net income.

Comprehensive Income, Policy [Policy Text Block]

Other Comprehensive Income

Segment Reporting, Policy [Policy Text Block]

Segment Information

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Note_1_Business_Organization_a1

Note 1 - Business Organization and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	'
		Presentation as of December 31, 2012
	(In thousands)	As Previously			Revision			As
		Reported			Adjustment			Revised

	Gross profit	$	78,457		$	(78,457	)	$	-
	Total costs and expenses		(70,140	)		(3,030	)		(73,170	)

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
		December 31,
	(In thousands)	2013			2012
	Deferred revenue, current	$	1,365		$	3,700
	Deferred revenue, non-current		6,169			7,093
		$	7,534		$	10,793

	Deferred revenue to related parties, included in total deferred revenue:
	Deferred revenue to related parties, current	$	477		$	479
	Deferred revenue to related parties, non-current		4,925			5,386
	Total	$	5,402		$	5,865
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Year Ended December 31,
		2013			2012			2011
	Expected volatility	65%	-	75%	62%	-	64%	55%	-	64%
	Risk-free interest rate	1.23%	-	1.40%	0.76%	-	1.60%	1.30%	-	3.30%
	Expected term (in years)	5.5	-	6.25	5.5	-	6.25	2.1	-	6.25
	Expected dividend yield		0%			0%			0%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Year Ended December 31,
	(In thousands)	2013			2012			2011
	Research and development expense	$	293		$	535		$	234
	General and administrative expense		1,260			1,349			964
	Selling and marketing expense		191			349			172
	Total		1,744			2,233			1,370

	Employee stock-based compensation expense per basic and diluted share of common stock	$	0.04		$	0.05		$	0.03

Note_3_Net_Income_Loss_per_Sha1

Note 3 - Net Income (Loss) per Share (Tables)	12 Months Ended
Note 3 - Net Income (Loss) per Share (Tables)	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		December 31,
	(in thousands, except per share data)	2013		2012		2011
	Basic net income (loss) per share:
	Net income (loss)	$	6,419	$	4,836	$	(17,306	)

	Weighted average class A and B common shares outstanding		41,716		41,660		41,839

	Basic net income (loss) per share	$	0.15	$	0.12	$	(0.41	)

	Diluted net income (loss) per share:
	Net income (loss)	$	6,419	$	4,836	$	(17,306	)

	Weighted average class A and B common shares outstanding for diluted net income per share		41,716		41,660		41,839

	Assumed exercise of stock options under the treasury stock method		828		125		-
			42,544		41,785		41,839

	Diluted net income (loss) per share	$	0.15	$	0.12	$	(0.41	)
Schedule of Potentially Dilutive Securities [Table Text Block]	'
		December 31,
	(In thousands)	2013		2012		2011
	Employee stock options		2,129		2,811		-
	Non-employee stock options		410		450		-
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		December 31,
	(In thousands)	2013		2012		2011
	Employee stock options		530		596		3,595
	Non-employee stock options		-		-		450

Note_4_Current_and_NonCurrent_1

Note 4 - Current and Non-Current Investments (Tables)	12 Months Ended
Note 4 - Current and Non-Current Investments (Tables)	Dec. 31, 2013
Investments Schedule [Abstract]	'
Available-for-sale Securities [Table Text Block]	'
		31-Dec-13
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
	(In thousands)	Cost		Gains		Losses			Fair Value
	Current:
	U.S. government securities	$	1,000	$	-	$	-		$	1,000
	U.S. government agencies		9,048		3		-			9,051
	Certificates of deposits		3,500		-		-			3,500
	Corporate bonds		752		-		-			752
	Municipal securities		1,700		-		-			1,700
	Total	$	16,000	$	3	$	-		$	16,003

	Non-current:
	U.S. government agencies	$	4,212	$	-	$	(3	)	$	4,209
	Certificates of deposits	$	2,500						$	2,500
	Corporate bonds		511		-		(1	)		510
	Total	$	7,223	$	-	$	(4	)	$	7,219
		31-Dec-12
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
	(In thousands)	Cost		Gains		Losses			Fair Value
	Current:
	U.S. commercial paper	$	2,499	$	-	$	-		$	2,499
	U.S. government securities		251		-		-			251
	Corporate bonds		500		-		-			500
	Variable rate demand notes		2,785		-		-			2,785
	Total	$	6,035	$	-	$	-		$	6,035

	Non-current:
	U.S. government securities	$	10,131	$	2	$	(3	)	$	10,130
	Certificates of deposits		3,000		-		-			3,000
	Corporate bonds		1,281		-		(3	)		1,278
	Total	$	14,412	$	2	$	(6	)	$	14,408
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		Fair Value Measurements at Reporting Date Using
	31-Dec-13	Quoted Prices		Significant		Significant
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs
		Assets
	(In thousands)	(Level 1)		(Level 2)		(Level 3)			Total
	U.S. government securities	$	-	$	1,000	$	-		$	1,000
	U.S. government agencies		-		13,260		-			13,260
	U.S. commercial paper		-		6,449		-			6,449
	Municipal securities		-		1,700		-			1,700
	Certificates of deposits		-		6,000		-			6,000
	Corporate bonds		-		5,533		-			5,533
	Money market funds		5,955		-		-			5,955
	Total assets measured at fair value	$	5,955	$	33,942	$	-		$	39,897
		Fair Value Measurements at Reporting Date Using
	31-Dec-12	Quoted Prices		Significant		Significant
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs
		Assets
	(In thousands)	(Level 1)		(Level 2)		(Level 3)			Total
	U.S. government securities	$	-	$	10,130	$	-		$	10,130
	U.S. commercial paper		-		5,998		-			5,998
	Municipal securities		-		1,253		-			1,253
	Certificates of deposits		-		3,500		-			3,500
	Corporate bonds		-		6,286		-			6,286
	Money market funds		16,274		-		-			16,274
	Variable rate demand notes		-		2,785		-			2,785
	Total assets measured at fair value	$	16,274	$	29,952	$	-		$	46,226

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment (Tables)	12 Months Ended
Note 5 - Property and Equipment (Tables)	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		December 31,
	(In thousands)	2013			2012
	Computer and office machines	$	2,607		$	2,598
	Furniture and fixtures		480			434
	Leasehold improvements		1,444			1,478
	Total cost		4,531			4,510
	Less: accumulated depreciation		(3,375	)		(2,970	)
	Total	$	1,156		$	1,540

Note_7_Accrued_Expenses_Tables

Note 7 - Accrued Expenses (Tables)	12 Months Ended
Note 7 - Accrued Expenses (Tables)	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		December 31,
	(In thousands)	2013		2012
	Research and development costs	$	1,775	$	6,662
	Employee compensation		2,531		1,219
	Selling and marketing costs		584		487
	Legal service fees		14		830
	RESCULA milestones		-		500
	Other accrued expenses		778		897
	Total	$	5,682	$	10,595

Note_8_Other_Liabilities_Table

Note 8 - Other Liabilities (Tables)	12 Months Ended
Note 8 - Other Liabilities (Tables)	Dec. 31, 2013
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]	'
Other Liabilities [Table Text Block]	'
		December 31,
	(In thousands)	2013		2012
	Japan consumption tax payable	$	917	$	-
	Deferred leasehold incentive		255		373
	Deferred rent expense		341		408
	Other liabilities		637		472
	Total	$	2,150	$	1,253

Note_9_Commitments_and_Conting1

Note 9 - Commitments and Contingencies (Tables)	12 Months Ended
Note 9 - Commitments and Contingencies (Tables)	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	(In thousands of U.S. dollars)	December 31,
	(In thousands of U.S. dollars)	2013
	2014	$	1,273
	2015		1,093
	2016		1,084
	2017		139
	2018		-
	Total minimum lease payments	$	3,589

Note_10_Related_Party_Transact1

Note 10 - Related Party Transactions (Tables)	12 Months Ended
Note 10 - Related Party Transactions (Tables)	Dec. 31, 2013
Note 10 - Related Party Transactions (Tables) [Line Items]	'
Schedule of Related Party Transactions [Table Text Block]	'
		Year Ended December 31,
	(In thousands)	2013		2012		2011
	Clinical supplies	$	827	$	1,450	$	72
	Other research and development services		194		466		104
	Commercial supplies		14,902		3,288		155
		$	15,923	$	5,204	$	331
Deferred Revenue [Member]	'
Note 10 - Related Party Transactions (Tables) [Line Items]	'
Schedule of Related Party Transactions [Table Text Block]	'
		Year Ended December 31,
	(In thousands)	2013		2012
	Deferred revenue, current	$	477	$	479
	Deferred revenue, non-current		4,925		5,386
		$	5,402	$	5,865

Note_11_Notes_Payable_Tables

Note 11 - Notes Payable (Tables)	12 Months Ended
Note 11 - Notes Payable (Tables)	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		Fair Value		Carrying Value
		December 31,		Year Ended December 31,
	(In thousands)	2013		2013		2012
	Loan agreements	$	19,008	$	19,008	$	11,600
	Promissory notes, Sellers of SAG		34,889		33,712		41,251
		$	53,897	$	52,720	$	52,851

	Notes payable, current			$	26,892	$	19,129
	Notes payable, non-current				25,828		33,722
				$	52,720	$	52,851

Note_12_Collaboration_and_Lice1

Note 12 - Collaboration and License Agreements (Tables)	12 Months Ended
Note 12 - Collaboration and License Agreements (Tables)	Dec. 31, 2013
Note 12 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
		December 31,
	(In thousands)	2013		2012
	Deferred revenue, current	$	1,365	$	3,700
	Deferred revenue, non-current		6,169		7,093
		$	7,534	$	10,793

	Deferred revenue to related parties, included in total deferred revenue:
	Deferred revenue to related parties, current	$	477	$	479
	Deferred revenue to related parties, non-current		4,925		5,386
	Total	$	5,402	$	5,865
Abbott [Member]	'
Note 12 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
		Cash		Revenue Recognized for the						Accounts		Foreign			Amount
		Received		Year Ended December 31,						Receivable for		Currency			Deferred at
		Through								the Year Ended					December 31,
		December 31,								December 31,
	(In thousands)	2013		Through 2011		2012		2013		2013		Effects			2013
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	846	$	137	$	52	$	52	$	-	$	50		$	555

	Research and development revenue:
	Up-front payment - remainder	$	9,154	$	9,103	$	199	$	-	$	-	$	(148	)	$	-
	Development milestone payment		27,500		12,598		15,157		-		-		(255	)		-
	Total	$	36,654	$	21,701	$	15,356	$	-	$	-	$	(403	)	$	-


	Product sales revenue:	$	19,017	$	-	$	5,023	$	15,807	$	2,076	$	263		$	-
Takeda [Member]	'
Note 12 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
		Cash		Revenue Recognized for the						Accounts		Amount
		Received		Year Ended December 31,						Receivable for		Deferred at
		Through								the Year Ended		December 31,
		December 31,								December 31,
	(In thousands)	2013		Through 2011		2012		2013		2013 (1)		2013
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	2,375	$	1,052	$	147	$	147	$	-	$	1,029

	Research and development revenue:
	Up-front payment - remainder	$	17,624	$	17,624	$	-	$	-	$	-	$	-
	Development milestones		140,000		130,000		-		10,000		-		-
	Reimbursement of research and development expenses		114,670		100,262		6,189		10,354		2,554		419
	Total	$	272,294	$	247,886	$	6,189	$	20,354	$	2,554	$	419

	Product royalty revenue	$	276,598	$	188,631	$	50,696	$	52,100	$	14,829	$	-

	Co-promotion revenue	$	29,453	$	25,816	$	3,576	$	61	$	-	$	-

Note_13_Stockholders_Equity_Ta

Note 13 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise		Remaining
					Price Per		Contractual
					Share		Term (Years)
	Options outstanding, December 31, 2012		156,400		$	10
	Options expired		(10,200	)		10
	Options outstanding, December 31, 2013		146,200			10		2.34	$	-
	Options exercisable, December 31, 2013		146,200			10		2.34	$	-
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise		Remaining
					Price Per		Contractual
					Share		Term (Years)
	Options outstanding, December 31, 2012		3,251,493		$	4.83
	Options granted		204,250			7.36
	Options exercised		(557,836	)		4.43
	Options forfeited		(334,879	)		5.36
	Options expired		(49,965	)		6.61
	Options outstanding, December 31, 2013		2,513,063			5.03		7.34	$	11,346,066
	Options exercisable, December 31, 2013		1,143,912			5.41		6.97	$	4,919,233
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise		Remaining
					Price Per		Contractual
					Share		Term (Years)
	Options outstanding, December 31, 2012		450,000		$	5.85
	Options exercised		(40,000	)		5.85
	Options outstanding, December 31, 2013		410,000			5.85		1.31	$	1,455,500
	Options exercisable, December 31, 2013		410,000			5.85		1.31	$	1,455,500

Note_14_Income_Taxes_Tables

Note 14 - Income Taxes (Tables)	12 Months Ended
Note 14 - Income Taxes (Tables)	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	'
		Year Ending December 31,
		2013			2012			2011
	U.S.	$	9,175		$	8,580		$	(9,670	)
	Foreign		1,172			(828	)		(12,244	)
		$	10,347		$	7,752		$	(21,914	)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
		Year Ended December 31,
	(In thousands)	2013			2012			2011
	Current tax provision (benefit):
	U.S. Federal	$	5,198		$	1,431		$	(597	)
	U.S. State		1,008			658			(194	)
	Foreign		(582	)		51			550
	Total current tax provision (benefit)		5,624			2,140			(241	)

	Deferred provision (benefit):
	U.S. Federal		(1,783	)		1,248			(1,369	)
	U.S. State		(279	)		(193	)		385
	Foreign		366			(279	)		(3,383	)
	Total deferred provision (benefit)		(1,696	)		776			(4,367	)

	Total income tax provision (benefit)	$	3,928		$	2,916		$	(4,608	)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		December 31,
		2013			2012
	(In thousands)
	Deferred tax assets:
	Foreign net operating loss carry-forwards	$	2,538		$	5,132
	State net operating loss carry-forwards		38			100
	Deferred revenue		2,143			2,431
	Accrued expenses		1,637			1,316
	Tax benefits on stock options		2,378			1,832
	Inventory		1,243			-
	Other		220			388
	Gross deferred tax assets		10,197			11,199

	Deferred tax liabilities:
	Property and equipment		(202	)		(272	)
	Intangibles		(7,070	)		(6,884	)
	Gross deferred tax liabilities		(7,272	)		(7,156	)

	Less: valuation allowance		(1,751	)		(4,142	)
	Net deferred tax assets (liabilities)	$	1,174		$	(99	)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		Year Ended December 31,
	(In thousands)	2013			2012			2011
	Federal tax provision (benefit)		35	%		34	%		34	%
	State taxes, net of federal tax benefit		5.2	%		7.5	%		0.4	%
	General business credits		0	%		-0.5	%		1.6	%
	Changes in valuation allowance		-22.3	%		-3.7	%		-3.7	%
	Nondeductible expenses		1.3	%		1.7	%		-0.2	%
	Stock based compensation		-2.9	%		12.7	%		-1.9	%
	Impact of intangible transfer		7.7	%		-18.6	%		-4.7	%
	Impact of uncertain tax positions		-0.1	%		-4.2	%		-0.2	%
	Adjustment to deferred tax asset		11.8	%		-10.4	%		0.1	%
	Impact of foreign operations		1.8	%		6.4	%		-4.6	%
	Change in tax rates		0.6	%		12.4	%		-0.1	%
	Changes in other tax matters		-0.1	%		0.3	%		0.4	%
			38	%		37.6	%		21.1	%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	'
		Year Ended December 31,
		2013			2012			2011
	Balance at January 1	$	979		$	1,226		$	1,245
	Increases for tax positions taken during prior periods		4			207			22
	Decreases in unrecognized tax benefits related to settlements with taxing authorities		(467	)		(536	)		(71	)
	Increases for tax positions taken during current period		34			82			30
	Balance at December 31	$	550		$	979		$	1,226

Note_15_Segment_Reporting_Tabl

Note 15 - Segment Reporting (Tables)	12 Months Ended
Note 15 - Segment Reporting (Tables)	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	(In thousands)	Americas			Europe			Asia			Consolidated
	Year Ended December 31, 2013
	Research and development revenue	$	20,354		$	-		$	-		$	20,354
	Product royalty revenue		52,100			-			-			52,100
	Product sales revenue		556			62			15,807			16,425
	Co-promotion revenue		61			-			-			61
	Contract and collaboration revenue		566			46			42			654
	Total revenues		73,637			108			15,849			89,594
	Cost of goods sold		3,588			15			8,799			12,402
	Research and development expenses		11,090			5,445			4,989			21,524
	Depreciation and amortization		736			716			36			1,488
	Other operating expenses		35,911			5,900			3,173			44,984
	Income (loss) from operations		22,312			(11,968	)		(1,148	)		9,196
	Interest income		112			11			1			124
	Interest expense		(1,427	)		(302	)		(165	)		(1,894	)
	Other non-operating expense, net		(14	)		(166	)		3,101			2,921
	Income (loss) before income taxes	$	20,983		$	(12,425	)	$	1,789		$	10,347
	Capital expenditures	$	40		$	105		$	23		$	168
	(In thousands)	Americas			Europe			Asia			Consolidated
	Year Ended December 31, 2012
	Research and development revenue	$	6,189		$	-		$	15,356		$	21,545
	Product royalty revenue		50,696			-			-			50,696
	Product sales revenue		-			14			5,023			5,037
	Co-promotion revenue		3,576			-			-			3,576
	Contract and collaboration revenue		565			16			52			633
	Total revenues		61,026			30			20,431			81,487
	Cost of goods sold		98			9			2,923			3,030
	Research and development expenses		7,809			9,571			3,912			21,292
	Depreciation and amortization		484			964			40			1,488
	Other operating expenses		41,410			2,993			2,957			47,360
	Income (loss) from operations		11,225			(13,507	)		10,599			8,317
	Interest income		161			16			2			179
	Interest expense		-			(2,183	)		(163	)		(2,346	)
	Other non-operating expense, net		77			(187	)		1,712			1,602
	Income (loss) before income taxes	$	11,463		$	(15,861	)	$	12,150		$	7,752
	Capital expenditures	$	401		$	3,470		$	-		$	3,871

	Year Ended December 31, 2011
	Research and development revenue	$	8,033		$	-		$	1,216		$	9,249
	Product royalty revenue		41,517			-			-			41,517
	Co-promotion revenue		3,378			-			-			3,378
	Contract and collaboration revenue		565			-			52			617
	Total revenues		53,493			-			1,268			54,761
	Research and development expenses		24,058			4,354			5,085			33,497
	Settlement for legal dispute		(11,100	)		-			-			(11,100	)
	Depreciation and amortization		791			474			43			1,308
	Other operating expenses		46,326			1,092			1,327			48,745
	Income (loss) from operations		(6,582	)		(5,920	)		(5,187	)		(17,689	)
	Interest income		240			6			3			249
	Interest expense		-			(2,288	)		(167	)		(2,455	)
	Other non-operating expense, net		(42	)		(1,884	)		(93	)		(2,019	)
	Income (loss) before income taxes	$	(6,384	)	$	(10,086	)	$	(5,444	)	$	(21,914	)
	Capital expenditures	$	145		$	6,006		$	133		$	6,284

	As of December 31, 2013
	Property and equipment, net	$	869		$	112		$	175		$	1,156
	Identifiable assets, net of intercompany loans and investments	$	95,350		$	23,843		$	17,780		$	136,973

	As of December 31, 2012
	Property and equipment, net	$	1,276		$	36		$	228		$	1,540
	Identifiable assets, net of intercompany loans and investments	$	87,731		$	25,465		$	14,600		$	127,796

Note_16_Quarterly_Financial_Da1

Note 16 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
Note 16 - Quarterly Financial Data (Unaudited) (Tables)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
		2013 Quarters Ended
	(In thousands, except per share data)	31-Dec		30-Sep			30-Jun			31-Mar
	Total revenues	$	24,490	$	21,163		$	27,023		$	16,919
	Income (loss) from operations	$	2,679	$	(1,044	)	$	10,169		$	(2,608	)
	Net income (loss)	$	2,153	$	1,291		$	6,119		$	(3,145	)
	Net income (loss) per share:
	Basic	$	0.05	$	0.03		$	0.15		$	(0.08	)
	Diluted	$	0.05	$	0.03		$	0.14		$	(0.08	)
		2012 Quarters Ended
	(In thousands, except per share data)	31-Dec		30-Sep			30-Jun			31-Mar
	Total revenues	$	34,862	$	15,496		$	16,683		$	14,446
	Income (loss) from operations	$	12,966	$	(1,653	)	$	(2,674	)	$	(322	)
	Net income (loss)	$	13,532	$	(5,949	)	$	(819	)	$	(1,928	)
	Net income (loss) per share:
	Basic	$	0.33	$	(0.14	)	$	(0.02	)	$	(0.05	)
	Diluted	$	0.32	$	(0.14	)	$	(0.02	)	$	(0.05	)

Note_1_Business_Organization_a2

Note 1 - Business Organization and Basis of Presentation (Details)	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Number of prostone products that received marketing approval	2

Note_1_Business_Organization_a3

Note 1 - Business Organization and Basis of Presentation (Details) - Revision to Previously Issued Financial Statements (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Total costs and expenses	($80,398)	($73,170)	($72,450)
Scenario, Previously Reported [Member]	'	'	'
Gross profit	'	78,457	'
Total costs and expenses	'	-70,140	'
Restatement Adjustment [Member]	'	'	'
Gross profit	'	-78,457	'
Total costs and expenses	'	($3,030)	'

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Restricted Cash and Cash Equivalents	$28,600,000	$18,900,000	'	'
Cash, FDIC Insured Amount	16,400,000	16,800,000	'	'
PercentageOfDepositWithinFederallyInsuredLimits	17.10%	18.40%	'	'
Allowance for Doubtful Accounts Receivable	440,000	280,000	'	'
NumberOfWholesalersInConcentrationPercentage	3	'	'	'
Deferred Revenue	7,534,000	10,793,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate, Minimum	10.00%	10.00%	10.00%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate, Maximum	14.00%	14.00%	14.00%	'
Amortization period of deferred charges	'10 years	'	'	'
Benefit Related to Partial Reversal of Internal Transfer	'	1,900,000	'	'
Increase (Decrease) in Deferred Charges	'	-23,800,000	'	'
Increase (Decrease) in Deferred Tax Liabilities	'	-24,100,000	'	'
Deferred Costs	5,200,000	5,900,000	'	'
Amortization of Deferred Charges	673,000	77,000	'	'
Liability for Uncertain Tax Positions	679,000	1,100,000	'	'
Liability for Uncertain Tax Positions, Current	'	42,000	'	'
Unrecognized Tax Benefits, Period Increase (Decrease)	-452,000	'	'	'
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	42,000	'	'	'
Open Tax Year	'2013	'2012	'2011	'2010
Number of Reportable Segments	3	'	'	'
Takeda [Member] \| Sales Revenue, Goods, Net [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Concentration Risk, Percentage	81.30%	74.40%	96.90%	'
Takeda [Member] \| Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Concentration Risk, Percentage	88.20%	98.00%	'	'
Abbott [Member] \| Sales Revenue, Goods, Net [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Concentration Risk, Percentage	17.60%	19.30%	2.30%	'
Wholesale [Member] \| Customer Concentration Risk [Member] \| Sales Revenue, Product Line [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Concentration Risk, Percentage	96.20%	'	'	'
Computer and Office Machines [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'4 years	'	'	'
Furniture and Fixtures [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'7 years	'	'	'
Leasehold Improvements [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'10 years	'	'	'
Other Current Liabilities [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Liability for Uncertain Tax Positions, Current	42,000	660,000	'	'
Other Liabilities [Member]	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Liability for Uncertain Tax Positions, Noncurrent	$637,000	$471,000	'	'

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Deferred Revenue (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2005	Mar. 31, 2003
Deferred Revenue Arrangement [Line Items]	'	'	'	'
Deferred revenue, current	$1,365,000	$3,700,000	'	'
Deferred revenue, noncurrent	6,169,000	7,093,000	'	'
Deferred revenue	7,534,000	10,793,000	'	'
R-Tech [Member]	'	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'	'
Deferred revenue, current	477,000	479,000	'	'
Deferred revenue, noncurrent	4,925,000	5,386,000	6,000,000	6,000,000
Deferred revenue	$5,402,000	$5,865,000	'	'

Note_2_Summary_of_Significant_4

Note 2 - Summary of Significant Accounting Policies (Details) - Assumptions Used to Estimate Fair Value of Stock Options Granted	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Minimum [Member]	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) - Assumptions Used to Estimate Fair Value of Stock Options Granted [Line Items]	'	'	'
Expected volatility	65.00%	62.00%	55.00%
Risk-free interest rate	1.23%	0.76%	1.30%
Expected term (in years)	'5 years 6 months	'5 years 6 months	'2 years 36 days
Maximum [Member]	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) - Assumptions Used to Estimate Fair Value of Stock Options Granted [Line Items]	'	'	'
Expected volatility	75.00%	64.00%	64.00%
Risk-free interest rate	1.40%	1.60%	3.30%
Expected term (in years)	'6 years 3 months	'6 years 3 months	'6 years 3 months

Note_2_Summary_of_Significant_5

Note 2 - Summary of Significant Accounting Policies (Details) - Employee Stock Based Compensation Expense (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Employee stock-based compensation expense	$1,744	$2,233	$1,370
Employee stock-based compensation expense per basic and diluted share of common stock (in Dollars per share)	$0.04	$0.05	$0.03
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Employee stock-based compensation expense	293	535	234
General and Administrative Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Employee stock-based compensation expense	1,260	1,349	964
Selling and Marketing Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Employee stock-based compensation expense	$191	$349	$172

Note_3_Net_Income_Loss_per_Sha2

Note 3 - Net Income (Loss) per Share (Details) - Net Income (Loss) Per Share (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basic net income (loss) per share:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) (in Dollars)	$2,153	$1,291	$6,119	($3,145)	$13,532	($5,949)	($819)	($1,928)	$6,419	$4,836	($17,306)
Weighted average class A and B common shares outstanding	'	'	'	'	'	'	'	'	41,716	41,660	41,839
Basic net income (loss) per share (in Dollars per share)	$0.05	$0.03	$0.15	($0.08)	$0.33	($0.14)	($0.02)	($0.05)	$0.15	$0.12	($0.41)
Assumed exercise of stock options under the treasury stock method	'	'	'	'	'	'	'	'	828	125	'
	'	'	'	'	'	'	'	'	42,544	41,785	41,839
Diluted net income (loss) per share (in Dollars per share)	$0.05	$0.03	$0.14	($0.08)	$0.32	($0.14)	($0.02)	($0.05)	$0.15	$0.12	($0.41)

Note_3_Net_Income_Loss_per_Sha3

Note 3 - Net Income (Loss) per Share (Details) - Potentially Dilutive Securities	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 3 - Net Income (Loss) per Share (Details) - Potentially Dilutive Securities [Line Items]	'	'	'
Potentially dilutive securities	828	125	'
Employee Stock Option [Member]	'	'	'
Note 3 - Net Income (Loss) per Share (Details) - Potentially Dilutive Securities [Line Items]	'	'	'
Potentially dilutive securities	2,129	2,811	0
Non-Employee Stock Options [Member]	'	'	'
Note 3 - Net Income (Loss) per Share (Details) - Potentially Dilutive Securities [Line Items]	'	'	'
Potentially dilutive securities	410	450	0

Note_3_Net_Income_Loss_per_Sha4

Note 3 - Net Income (Loss) per Share (Details) - Antidilutive Securities	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Stock Options [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities	530	596	3,595
Non-Employee Stock Options [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities	'	'	450

Note_4_Current_and_NonCurrent_2

Note 4 - Current and Non-Current Investments (Details) - Current and Non-Current Investments (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
US Government and Government Agencies and Authorities [Member] \| Current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	$1,000	$251
Fair Value	1,000	251
US Government and Government Agencies and Authorities [Member] \| Non-current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	'	10,131
Unrealized Gains	'	2
Unrealized Losses	'	-3
Fair Value	'	10,130
US Government Agencies Debt Securities [Member] \| Current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	9,048	'
Unrealized Gains	3	'
Fair Value	9,051	'
US Government Agencies Debt Securities [Member] \| Non-current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	4,212	'
Unrealized Losses	-3	'
Fair Value	4,209	'
Certificates of Deposit [Member] \| Current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	3,500	'
Fair Value	3,500	'
Certificates of Deposit [Member] \| Non-current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	2,500	3,000
Fair Value	2,500	3,000
Corporate Bond Securities [Member] \| Current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	752	500
Fair Value	752	500
Corporate Bond Securities [Member] \| Non-current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	511	1,281
Unrealized Losses	-1	-3
Fair Value	510	1,278
Municipal Notes [Member] \| Current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	1,700	'
Fair Value	1,700	'
Current [Member] \| Current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	16,000	6,035
Unrealized Gains	3	'
Fair Value	16,003	6,035
Non-current [Member] \| Non-current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	7,223	14,412
Unrealized Gains	'	2
Unrealized Losses	-4	-6
Fair Value	7,219	14,408
Commercial Paper [Member] \| Current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	'	2,499
Fair Value	'	2,499
Variable Rate Demand Obligation [Member] \| Current [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	'	2,785
Fair Value	'	$2,785

Note_4_Current_and_NonCurrent_3

Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	$5,955	$16,274
Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	33,942	29,952
Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	39,897	46,226
US Government and Government Agencies and Authorities [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	1,000	10,130
US Government and Government Agencies and Authorities [Member] \| Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	1,000	10,130
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	13,260	'
US Government Agencies Debt Securities [Member] \| Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	13,260	'
Commercial Paper [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	6,449	5,998
Commercial Paper [Member] \| Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	6,449	5,998
Municipal Notes [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	1,700	1,253
Municipal Notes [Member] \| Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	1,700	1,253
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	6,000	3,500
Certificates of Deposit [Member] \| Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	6,000	3,500
Corporate Bond Securities [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	5,533	6,286
Corporate Bond Securities [Member] \| Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	5,533	6,286
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	5,955	16,274
Money Market Funds [Member] \| Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	5,955	16,274
Variable Rate Demand Obligation [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	2,785
Variable Rate Demand Obligation [Member] \| Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	$2,785

Note_5_Property_and_Equipment_1

Note 5 - Property and Equipment (Details) (USD $)	12 Months Ended
Note 5 - Property and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Abstract]	'	'	'
Depreciation	$512,000	$542,000	$591,000

Note_5_Property_and_Equipment_2

Note 5 - Property and Equipment (Details) - Property and Equipment (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	$4,531	$4,510
Less: accumulated depreciation	-3,375	-2,970
Total	1,156	1,540
Computer and Office Machines [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	2,607	2,598
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	480	434
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	$1,444	$1,478

Note_6_Intangible_Assets_Detai

Note 6 - Intangible Assets (Details) (USD $)	1 Months Ended	4 Months Ended	12 Months Ended
Note 6 - Intangible Assets (Details) (USD $)	30-May-13	Apr. 30, 2009	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 6 - Intangible Assets (Details) [Line Items]	'	'	'	'	'
Payments to Acquire Intangible Assets	'	'	'	$3,000,000	$3,000,000
Other Noncurrent Assets [Member] \| 2009 R-Tech Agreement [Member]	'	'	'	'	'
Note 6 - Intangible Assets (Details) [Line Items]	'	'	'	'	'
Finite-lived Intangible Assets Acquired	'	'	3,400,000	'	'
2009 R-Tech Agreement [Member] \| Non-current Prepaid Inventory [Member]	'	'	'	'	'
Note 6 - Intangible Assets (Details) [Line Items]	'	'	'	'	'
Payments to Acquire Other Productive Assets	'	'	85,000	'	'
Asset Impairment Charges	'	'	85,000	'	'
2009 R-Tech Agreement [Member]	'	'	'	'	'
Note 6 - Intangible Assets (Details) [Line Items]	'	'	'	'	'
Payments to Acquire Intangible Assets	'	3,500,000	'	'	'
MilestonePaymentsMaximumAmount	'	5,000,000	'	'	'
MilestonePayments	500,000	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'10 years	'	'
Amortization of Intangible Assets	'	'	341,000	341,000	341,000
Finite-Lived Intangible Assets, Annual Amortization Expense	'	'	341,000	'	'
Finite-Lived Intangible Assets, Net	'	'	1,800,000	2,100,000	'
2011 R-Tech Agreement [Member]	'	'	'	'	'
Note 6 - Intangible Assets (Details) [Line Items]	'	'	'	'	'
Payments to Acquire Intangible Assets	'	'	6,000,000	'	'
MilestonePaymentsMaximumAmount	'	'	100,000,000	'	'
Finite-lived Intangible Assets Acquired	'	'	6,000,000	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'10 years	'	'
Amortization of Intangible Assets	'	'	613,000	613,000	613,000
Finite-Lived Intangible Assets, Annual Amortization Expense	'	'	613,000	'	'
Finite-Lived Intangible Assets, Net	'	'	$4,400,000	$4,900,000	'

Note_7_Accrued_Expenses_Detail

Note 7 - Accrued Expenses (Details) - Accrued Expenses (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Accrued Expenses [Abstract]	'	'
Research and development costs	$1,775	$6,662
Employee compensation	2,531	1,219
Selling and marketing costs	584	487
Legal service fees	14	830
RESCULA milestones	'	500
Other accrued expenses	778	897
Total	$5,682	$10,595

Note_8_Other_Liabilities_Detai

Note 8 - Other Liabilities (Details) - Other Liabilities (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Other Liabilities [Abstract]	'	'
Japan consumption tax payable	$917	'
Deferred leasehold incentive	255	373
Deferred rent expense	341	408
Other liabilities	637	472
Total	$2,150	$1,253

Note_9_Commitments_and_Conting2

Note 9 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 9 - Commitments and Contingencies (Details) [Line Items]	'	'	'
Operating Leases, Rent Expense	$1.30	$1.60	$1.60
Future Estimated Research and Development Costs	6.8	'	'
Guarantee of Indebtedness of Others [Member]	'	'	'
Note 9 - Commitments and Contingencies (Details) [Line Items]	'	'	'
Loss Contingency, Range of Possible Loss, Maximum	2.5	'	'
Loss Contingency, Estimate of Possible Loss	$2.20	'	'

Note_9_Commitments_and_Conting3

Note 9 - Commitments and Contingencies (Details) - Future Minimum, Non-Cancelable Lease Payments (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Future Minimum, Non-Cancelable Lease Payments [Abstract]	'
2014	$1,273
2015	1,093
2016	1,084
2017	139
Total minimum lease payments	$3,589

Note_10_Related_Party_Transact2

Note 10 - Related Party Transactions (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Mar. 07, 2003

Mar. 31, 2003

Mar. 07, 2003

Mar. 31, 2003

Feb. 28, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 24, 2005

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 04, 2006

Dec. 31, 2013

Dec. 31, 2012

Nov. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Mar. 31, 2003

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2013

Oct. 31, 2012

Dec. 31, 2005

Mar. 31, 2003

Mar. 07, 2003

RUG-015 and Lubiprostone [Member]

Lubiprostone [Member]

RUG-015 [Member]

Up-front Payment Arrangement [Member]

Milestone Payment Arrangement [Member]

Clinical Supplies [Member]

2005 R-Tech Agreement [Member]

Commercial supplies [Member]

2006 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

Research and Development Services [Member]

R-Tech [Member]

2009 R-Tech Agreement [Member]

R-Tech [Member]

Ueno Fine Chemical [Member]

Initial Execution Of Agreement [Member]

Commencement of Second Phase 2 First Phase 3 [Member]

Initial Execution Of Agreement [Member]

Commencement of First Phase 2 Trial [Member]

R-Tech [Member]

Clinical Supplies [Member]

Note 10 - Related Party Transactions (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

$1,000,000

$2,000,000

$3,000,000

$2,000,000

Proceeds from Related Party

2,000,000

3,000,000

250,000

500,000

2,000,000

250,000

6,000,000

1,000,000

Deferred Revenue, Noncurrent

6,169,000

7,093,000

2,000,000

250,000

6,000,000

4,925,000

5,386,000

6,000,000

Contracts Revenue

419,000

Related Party Transaction, Purchases from Related Party

827,000

1,400,000

72,000

124,000

125,000

673,000

10,000

14,900,000

3,100,000

166,000

194,000

466,000

104,000

Manufacturing and Supply Agreement Period

'20 years

'2 years

Mutual written termination period

'90 days

Manufacturing and Supply Agreement, Additional Period

'2 years

Purchase Commitment, Remaining Minimum Amount Committed

5,600,000

SignificantPurchaseCommitmentSatisfiedAmount

$5,600,000

Lessee Leasing Arrangements, Operating Leases, Term of Contract

'30 years

Remaining Lease Term

'20 years

Note_10_Related_Party_Transact3

Note 10 - Related Party Transactions (Details) - Expenses Under Agreements With R-Tech (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Party Transaction [Line Items]	'	'	'
Expenses related to R-Tech	$15,923	$5,204	$331
Clinical Supplies [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Expenses related to R-Tech	827	1,450	72
Other research and development services [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Expenses related to R-Tech	194	466	104
Commercial supplies [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Expenses related to R-Tech	$14,902	$3,288	$155

Note_10_Related_Party_Transact4

Note 10 - Related Party Transactions (Details) - Amounts Included In Deferred Revenue Resulting From Deferral Of Upfront Payments Relating To Exclusive Supply Agreements With R-Tech (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2005	Mar. 31, 2003
Related Party Transaction [Line Items]	'	'	'	'
Deferred revenue, current	$1,365,000	$3,700,000	'	'
Deferred revenue, non-current	6,169,000	7,093,000	'	'
	7,534,000	10,793,000	'	'
R-Tech [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Deferred revenue, current	477,000	479,000	'	'
Deferred revenue, non-current	4,925,000	5,386,000	6,000,000	6,000,000
	$5,402,000	$5,865,000	'	'

Note_11_Notes_Payable_Details

Note 11 - Notes Payable (Details)

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 01, 2013

Nov. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Nov. 30, 2010

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

USD ($)

Ueno Trust [Member]

Kuno and Ueno Trust [Member]

Tokyo-Mitsubishi Bank [Member]

Mizuho Bank Limited [Member]

Subordinated Unsecured Promissory Notes [Member]

London Interbank Offered Rate (LIBOR) [Member]

Subordinated Unsecured Promissory Notes [Member]

Secured Debt [Member]

TIBOR [Member]

Secured Debt [Member]

USD ($)

Subordinated Unsecured Promissory Notes [Member]

USD ($)

JPY (¥)

USD ($)

Secured Debt [Member]

USD ($)

JPY (¥)

USD ($)

Note 11 - Notes Payable (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity (in Yen)

$11,600,000

¥ 1,000,000,000

$10,600,000

¥ 1,000,000,000

Line of Credit Facility, Maximum Borrowing Capacity

11,600,000

1,000,000,000

10,600,000

1,000,000,000

LineOfCreditFacilityPotentialTermExtensionPeriod

'1 year

Debt Instrument, Basis Spread on Variable Rate

4.00%

0.25%

1.00%

Line of Credit Facility, Interest Rate at Period End

1.22%

Line of Credit Facility, Amount Outstanding

9,500,000

11,600,000

9,500,000

PercentageCollateralToLoans

90.00%

100.00%

Interest-bearing Deposits in Banks and Other Financial Institutions

14,900,000

11,000,000

Weighted Average Rate Domestic Deposit

0.25%

0.30%

Line of Credit Facility, Interest Rate During Period

0.47%

Debt Instrument, Face Amount

25,900,000

51,900,000

Debt Instrument, Interest Rate, Stated Percentage

4.30%

Debt Instrument, Term

'7 years

Paid-in-Kind Interest

$2,024,000

$2,288,000

$2,200,000

$2,300,000

Note_11_Notes_Payable_Details_

Note 11 - Notes Payable (Details) - Notes Payable (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Note 11 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	$53,897	'
Note Payable Carrying Value	52,720	52,851
Notes payable, current	26,892	19,129
Notes payable, non-current	25,828	33,722
Mizuho Bank Limited [Member]	'	'
Note 11 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	19,008	'
Note Payable Carrying Value	19,008	11,600
SAG [Member]	'	'
Note 11 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	34,889	'
Note Payable Carrying Value	$33,712	$41,251

Note_12_Collaboration_and_Lice2

Note 12 - Collaboration and License Agreements (Details)

12 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Sep. 30, 2011

Dec. 31, 2006

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2009

Jun. 30, 2013

Oct. 31, 2004

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2004

Apr. 29, 2008

Jun. 30, 2007

Oct. 31, 2004

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2006

USD ($)

Financial Guarantee [Member]

For Each Additional Indication [Member]

For Each New Formulation [Member]

Up Front Fee And Milestone Payment Arrangement [Member]

Milestone Payment Arrangement [Member]

Up-front Payment Arrangement [Member]

Reimbursement Of Research And Development Expenses [Member]

Research And Development Revenue [Member]

Takeda [Member]

Numab Agreement [Member]

Takeda [Member]

Abbott [Member]

Takeda [Member]

Abbott [Member]

Takeda [Member]

Collaboration Revenue [Member]

Abbott [Member]

Takeda [Member]

USD ($)

CHF

Maximum [Member]

USD ($)

CHF

USD ($)

Note 12 - Collaboration and License Agreements (Details) [Line Items]

Revenue Recognition, Milestone Method, Revenue Recognized

$37,500,000

$160,000,000

$15,000,000

$12,500,000

$10,000,000

$20,000,000

$50,000,000

Deferred Revenue

7,534,000

10,793,000

50,000,000

1,000,000

1,200,000

2,400,000

17,600,000

Deferred Revenue, Revenue Recognized

147,000

Royalty Revenue

52,100,000

50,696,000

41,517,000

52,100,000

50,700,000

41,500,000

Initial Funded Development Costs, Amount

30,000,000

Entity Funded Development Costs

20,000,000

Collaborative Funded Development Costs, Minimum

50,000,000

Deferred Revenue, Noncurrent

6,169,000

7,093,000

30,000,000

Contracts Revenue

30,000,000

Number of Studies in Joint Commercialization

Funding Labeling Studies, Percentage

70.00%

Company Funded Labeling Studies, Percentage

30.00%

Funded Development Costs, Counterparty Obligation, Amount

50,000,000

20,000,000

Research and Development Arrangement, Contract to Perform for Others, Compensation Earned

20,354,000

21,545,000

9,249,000

10,400,000

4,400,000

8,000,000

Copromotion Revenue

61,000

3,576,000

3,378,000

61,000

3,600,000

3,400,000

Guarantor Obligations, Maximum Exposure, Undiscounted (in Francs)

2,500,000

2,200,000

5,000,000

Guarantor Obligations, Maximum Exposure, Undiscounted

2,500,000

2,200,000

5,000,000

Guarantor Obligations, Collateral Deposited (in Francs)

2,200,000

Guarantor Obligations, Current Carrying Value (in Francs)

2,200,000

2,000,000

Guarantor Obligations, Current Carrying Value

2,200,000

2,000,000

Loss Contingency Accrual, Provision

$663,000

Note_12_Collaboration_and_Lice3

Note 12 - Collaboration and License Agreements (Details) - Cash Streams And Related Revenue Recognized Or Deferred Under Agreement (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]	'	'	'
Amount Deferred	$7,534,000	$10,793,000	'
Up Front Payment Remainder [Member] \| Abbott [Member] \| Research And Development Revenue [Member]	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'
Cash Received	9,154,000	'	'
Revenue Recognized	'	199,000	9,103,000
Foreign Currency Effects	-148,000	'	'
Development Milestone [Member] \| Abbott [Member] \| Research And Development Revenue [Member]	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'
Cash Received	27,500,000	'	'
Revenue Recognized	'	15,157,000	12,598,000
Foreign Currency Effects	-255,000	'	'
Abbott [Member] \| Collaborative Arrangement [Member]	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'
Cash Received	846,000	'	'
Revenue Recognized	52,000	52,000	137,000
Amount Deferred	555,000	'	'
Foreign Currency Effects	50,000	'	'
Abbott [Member] \| Research And Development Revenue [Member]	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'
Cash Received	36,654,000	'	'
Revenue Recognized	'	15,356,000	21,701,000
Foreign Currency Effects	-403,000	'	'
Abbott [Member] \| Product Sales Revenue [Member]	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'
Cash Received	19,017,000	'	'
Revenue Recognized	15,807,000	5,023,000	'
Accounts Receivable	2,076,000	'	'
Foreign Currency Effects	$263,000	'	'

Note_12_Collaboration_and_Lice4

Note 12 - Collaboration and License Agreements (Details) - Cash Streams And Related Revenue Recognized Or Deferred Under Agreement (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]	'		'	'
Amount Deferred	$7,534,000		$10,793,000	'
Up Front Payment Remainder [Member] \| Takeda [Member] \| Research And Development Revenue [Member]	'		'	'
Deferred Revenue Arrangement [Line Items]	'		'	'
Cash Received	17,624,000		'	'
Revenue Recognized	'		'	17,624,000
Accounts Receivable	'	[1]	'	'
Development Milestone [Member] \| Takeda [Member] \| Research And Development Revenue [Member]	'		'	'
Deferred Revenue Arrangement [Line Items]	'		'	'
Cash Received	140,000,000		'	'
Revenue Recognized	10,000,000		'	130,000,000
Accounts Receivable	'	[1]	'	'
Reimbursement Of Research And Development Expenses [Member] \| Takeda [Member] \| Research And Development Revenue [Member]	'		'	'
Deferred Revenue Arrangement [Line Items]	'		'	'
Cash Received	114,670,000		'	'
Revenue Recognized	10,354,000		6,189,000	100,262,000
Accounts Receivable	2,554,000	[1]	'	'
Amount Deferred	419,000		'	'
Takeda [Member] \| Collaborative Arrangement [Member]	'		'	'
Deferred Revenue Arrangement [Line Items]	'		'	'
Cash Received	2,375,000		'	'
Revenue Recognized	147,000		147,000	1,052,000
Accounts Receivable	'	[1]	'	'
Amount Deferred	1,029,000		'	'
Takeda [Member] \| Research And Development Revenue [Member]	'		'	'
Deferred Revenue Arrangement [Line Items]	'		'	'
Cash Received	272,294,000		'	'
Revenue Recognized	20,354,000		6,189,000	247,886,000
Accounts Receivable	2,554,000	[1]	'	'
Amount Deferred	419,000		'	'
Takeda [Member] \| Product Royalty Revenue [Member]	'		'	'
Deferred Revenue Arrangement [Line Items]	'		'	'
Cash Received	276,598,000		'	'
Revenue Recognized	52,100,000		50,696,000	188,631,000
Accounts Receivable	14,829,000	[1]	'	'
Takeda [Member] \| Co-promotion revenue [Member]	'		'	'
Deferred Revenue Arrangement [Line Items]	'		'	'
Cash Received	29,453,000		'	'
Revenue Recognized	61,000		3,576,000	25,816,000
Accounts Receivable	'	[1]	'	'

[1]	Includes billed and unbilled accounts receivable.

Note_13_Stockholders_Equity_De

Note 13 - Stockholders' Equity (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 07, 2009

2-May-11

Aug. 05, 2005

2-May-11

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Aug. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Aug. 30, 2012

Sep. 30, 2003

Oct. 18, 2007

Dec. 31, 2011

Dec. 31, 2013

Jun. 05, 2006

Jan. 11, 2013

Nov. 12, 2012

Sep. 11, 2011

Dec. 11, 2008

Dec. 31, 2013

Dec. 31, 2012

Mar. 03, 2014

Aug. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Oct. 07, 2009

Oct. 18, 2007

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 11, 2013

Per Year [Member]

Non-Employee Stock Options [Member]

Service Based Options [Member]

Market Condition Based Options [Member]

Time-Based Stock Options [Member]

Employee Stock Option [Member]

Class B Common Stock into Class A Common Stock [Member]

Common Class B [Member]

Common Class A [Member]

Stock Plan 2001 [Member]

Stock Incentive Plan 2006 [Member]

2006 Employee Stock Purchase Plan [Member]

Cantor Fitzgerald & Co [Member]

Stock Incentive Plan 2006 [Member]

Stock Plan 2001 [Member]

Stock Incentive Plan 2006 [Member]

S&R Technology Holdings, LLC [Member]

Stock Plan 2001 [Member]

Stock Incentive Plan 2006 [Member]

2006 Employee Stock Purchase Plan [Member]

Cantor Fitzgerald & Co [Member]

Cantor Sales Agreement [Member]

Non-employee Directors [Member]

Cantor Sales Agreement [Member]

Non-employee Directors [Member]

Maximum [Member]

Cantor Sales Agreement [Member]

Note 13 - Stockholders' Equity (Details) [Line Items]

Conversion of Stock, Shares Converted

26,191,050

Common Stock, Voting Rights, Votes per Share

Common Stock, Conversion Basis

'one-for-one

Common Stock, Shares, Outstanding

43,315,749

41,964,905

43,998,430

Sales Agreement, Common Stock, Maximum Aggregate Sales Price (in Dollars)

$20,000,000

Sales Agreement, Commission Rate as a Percentage of Gross Sales

3.00%

Stock Issued During Period, Shares, New Issues

749,383

Proceeds from Issuance of Common Stock (in Dollars)

5,281,000

5,300,000

Stock Repurchase Program, Authorized Amount (in Dollars)

5,000,000

2,000,000

10,000,000

Stock Repurchased During Period, Shares

67,762

270,043

Stock Repurchased During Period, Value (in Dollars)

336,000

1,300,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

8,500,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

510,000

1,699,508

873,352

2,572,860

30,000

204,250

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$5.85

$7.36

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

410,000

450,000

1,143,912

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

'1 year 120 days

'2 years 120 days

'6 years 354 days

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

30,000

5,986,937

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'4 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'10 years

Share-based Compensation Arrangement by Share-based Payment Award, Increase in Common Stock Available for Issuance as Percentage of Aggregate Number of Shares Outstanding

5.00%

Annual Increase in Number of Shares Issuance

500,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Grant

20,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage of Options

60.00%

40.00%

Share-based Compensation Arrangement by Share-based Payment Award Options, Vesting Percentage, Year One

40.00%

Share-Based Compensation Arrangement by Share-Based Payment Award, Target Price, Year One (in Dollars per share)

Share-based Compensation Arrangement by Share-based Payment Award Options, Vesting Percentage, Year Two

40.00%

Share-Based Compensation Arrangement by Share-Based Payment Award Target Price, Year Two (in Dollars per share)

$12

Share-Based Compensation Arrangement by Share-based Payment Award Options Vesting Percentage, Year Three

20.00%

Share-Based Compensation Arrangement by Share-Based Payment Award Target Price, Year Three (in Dollars per share)

$16

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

$7.36

$6.30

$1.81

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)

1,100,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'1 year 237 days

Common Stock, Capital Shares Reserved for Future Issuance

4,250,000

Common Stock, Shares Authorized

75,000,000

270,000,000

500,000

Share-Based Compensation, Percentage of Compensation to Purchase Common Stock

10.00%

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

95.00%

Stock Issued During Period, Shares, Employee Stock Purchase Plans

3,625

3,550

Stock Issued During Period, Value, Employee Stock Purchase Plan (in Dollars)

25,000

20,000

13,000

24,000

20,000

13,000

Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation (in Dollars)

$213,000

Note_13_Stockholders_Equity_De1

Note 13 - Stockholders' Equity (Details) - Employee Stock Option Activity (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
2001 Incentive Plan [Member]	'	'
Note 13 - Stockholders' Equity (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	146,200	156,400
Options Outstanding, Weighted Average Exercise Price Per Share (in Dollars per share)	$10	$10
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'2 years 124 days	'
Options exercisable	146,200	'
Options exercisable, Weighted Average Exercise Price Per Share (in Dollars per share)	$10	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'2 years 124 days	'
Options expired	-10,200	'
Options expired, Weighted Average Exercise Price Per Share (in Dollars per share)	$10	'
Stock Incentive Plan 2006 [Member]	'	'
Note 13 - Stockholders' Equity (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	2,513,063	3,251,493
Options Outstanding, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.03	$4.83
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'7 years 124 days	'
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	$11,346,066	'
Options granted	204,250	'
Options granted (in Dollars per share)	$7.36	'
Options exercised	-557,836	'
Options exercised, Weighted Average Exercise Price Per Share (in Dollars per share)	$4.43	'
Options forfeited	-334,879	'
Options forfeited (in Dollars per share)	$5.36	'
Options exercisable	1,143,912	'
Options exercisable, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.41	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'6 years 354 days	'
Options exercisable, Aggregate Intrinsic Value (in Dollars)	4,919,233	'
Options expired	-49,965	'
Options expired, Weighted Average Exercise Price Per Share (in Dollars per share)	$6.61	'
Non Employee Stock Plan 2001 [Member]	'	'
Note 13 - Stockholders' Equity (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	410,000	450,000
Options Outstanding, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.85	$5.85
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'1 year 113 days	'
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	1,455,500	'
Options exercised	-40,000	'
Options exercised, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.85	'
Options exercisable	410,000	'
Options exercisable, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.85	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'1 year 113 days	'
Options exercisable, Aggregate Intrinsic Value (in Dollars)	$1,455,500	'

Note_14_Income_Taxes_Details

Note 14 - Income Taxes (Details) (USD $)	12 Months Ended
Note 14 - Income Taxes (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$7,000,000	'	'	'
Operating Loss Carryforwards, Expiration Date	31-Dec-19	'	'	'
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	4,900,000	'	'	'
Deferred Tax Assets, Valuation Allowance	1,751,000	4,142,000	'	'
Valuation Allowance, Deferred Tax Asset, Change in Amount	-2,400,000	-325,000	-5,200,000	'
Amortization period of deferred charges	'10 years	'	'	'
Benefit Related to Partial Reversal of Internal Transfer	'	1,900,000	'	'
Increase (Decrease) in Deferred Charges	'	-23,800,000	'	'
Increase (Decrease) in Deferred Tax Liabilities	'	-24,100,000	'	'
Deferred Costs	5,200,000	5,900,000	'	'
Amortization of Deferred Charges	673,000	77,000	'	'
Liability for Uncertain Tax Positions	679,000	1,100,000	'	'
Liability for Uncertain Tax Positions, Current	'	42,000	'	'
Unrecognized Tax Benefits, Interest on Income Taxes Expense	22,000	42,000	69,000	'
Open Tax Year	'2013	'2012	'2011	'2010
Employee Stock Option [Member]	'	'	'	'
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'
Deferred Costs	5,200,000	'	'	'
Foreign Tax Authority [Member]	'	'	'	'
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'
Operating Loss Carryforwards	11,900,000	21,000,000	'	'
Domestic Tax Authority [Member]	'	'	'	'
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'
Operating Loss Carryforwards	0	0	'	'
Domestic Tax Authority [Member] \| Minimum [Member]	'	'	'	'
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'
Open Tax Year	'2009	'	'	'
Domestic Tax Authority [Member] \| Maximum [Member]	'	'	'	'
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'
Open Tax Year	'2011	'	'	'
Other Liabilities [Member]	'	'	'	'
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'
Liability for Uncertain Tax Positions, Noncurrent	$637,000	$471,000	'	'

Note_14_Income_Taxes_Details_I

Note 14 - Income Taxes (Details) - Income (Loss) Before Income Taxes (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income (Loss) Before Income Taxes [Abstract]	'	'	'
U.S.	$9,175	$8,580	($9,670)
Foreign	1,172	-828	-12,244
	$10,347	$7,752	($21,914)

Note_14_Income_Taxes_Details_P

Note 14 - Income Taxes (Details) - Provision (Benefit) for Income Taxes (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Provision (Benefit) for Income Taxes [Abstract]	'	'	'
U.S. Federal	$5,198	$1,431	($597)
U.S. State	1,008	658	-194
Foreign	-582	51	550
Total current tax provision (benefit)	5,624	2,140	-241
U.S. Federal	-1,783	1,248	-1,369
U.S. State	-279	-193	385
Foreign	366	-279	-3,383
Total deferred provision (benefit)	-1,696	776	-4,367
Total income tax provision (benefit)	$3,928	$2,916	($4,608)

Note_14_Income_Taxes_Details_D

Note 14 - Income Taxes (Details) - Deferred Tax Assets (Liabilities), Net (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Foreign net operating loss carry-forwards	$2,538	$5,132
State net operating loss carry-forwards	38	100
Deferred revenue	2,143	2,431
Accrued expenses	1,637	1,316
Tax benefits on stock options	2,378	1,832
Inventory	1,243	'
Other	220	388
Gross deferred tax assets	10,197	11,199
Deferred tax liabilities:	'	'
Property and equipment	-202	-272
Intangibles	-7,070	-6,884
Gross deferred tax liabilities	-7,272	-7,156
Less: valuation allowance	-1,751	-4,142
Net deferred tax assets (liabilities)	$1,174	($99)

Note_14_Income_Taxes_Details_I1

Note 14 - Income Taxes (Details) - Income Taxes on The Federal Statutory Rate	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes on The Federal Statutory Rate [Abstract]	'	'	'
Federal tax provision (benefit)	35.00%	34.00%	34.00%
State taxes, net of federal tax benefit	5.20%	7.50%	0.40%
General business credits	0.00%	-0.50%	1.60%
Changes in valuation allowance	-22.30%	-3.70%	-3.70%
Nondeductible expenses	1.30%	1.70%	-0.20%
Stock based compensation	-2.90%	12.70%	-1.90%
Impact of intangible transfer	7.70%	-18.60%	-4.70%
Impact of uncertain tax positions	-0.10%	-4.20%	-0.20%
Adjustment to deferred tax asset	11.80%	-10.40%	0.10%
Impact of foreign operations	1.80%	6.40%	-4.60%
Change in tax rates	0.60%	12.40%	-0.10%
Changes in other tax matters	-0.10%	0.30%	0.40%
	38.00%	37.60%	21.10%

Note_14_Income_Taxes_Details_U

Note 14 - Income Taxes (Details) - Unrecognized Tax Benefits Excluding Interest and Penalties (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Unrecognized Tax Benefits Excluding Interest and Penalties [Abstract]	'	'	'
Balance at January 1	$979	$1,226	$1,245
Increases for tax positions taken during prior periods	4	207	22
Decreases in unrecognized tax benefits related to settlements with taxing authorities	-467	-536	-71
Increases for tax positions taken during current period	34	82	30
Balance at December 31	$550	$979	$1,226

Note_15_Segment_Reporting_Deta

Note 15 - Segment Reporting (Details)	12 Months Ended
Note 15 - Segment Reporting (Details)	Dec. 31, 2013
Segment Reporting [Abstract]	'
Number of Reportable Segments	3

Note_15_Segment_Reporting_Deta1

Note 15 - Segment Reporting (Details) - Financial Information By Reportable Geographic Segment (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Research and development revenue	'	'	'	'	'	'	'	'	$20,354,000	$21,545,000	$9,249,000
Product royalty revenue	'	'	'	'	'	'	'	'	52,100,000	50,696,000	41,517,000
Product sales revenue	'	'	'	'	'	'	'	'	16,425,000	5,037,000	'
Co-promotion revenue	'	'	'	'	'	'	'	'	61,000	3,576,000	3,378,000
Contract and collaboration revenue	'	'	'	'	'	'	'	'	654,000	633,000	617,000
Total revenues	24,490,000	21,163,000	27,023,000	16,919,000	34,862,000	15,496,000	16,683,000	14,446,000	89,594,000	81,487,000	54,761,000
Cost of goods sold	'	'	'	'	'	'	'	'	12,402,000	3,030,000	'
Research and development expenses	'	'	'	'	'	'	'	'	21,524,000	21,292,000	33,497,000
Depreciation and amortization	'	'	'	'	'	'	'	'	1,488,000	1,488,000	1,308,000
Other operating expenses	'	'	'	'	'	'	'	'	44,984,000	47,360,000	48,745,000
Income (loss) from operations	2,679,000	-1,044,000	10,169,000	-2,608,000	12,966,000	-1,653,000	-2,674,000	-322,000	9,196,000	8,317,000	-17,689,000
Interest income	'	'	'	'	'	'	'	'	124,000	179,000	249,000
Interest expense	'	'	'	'	'	'	'	'	-1,894,000	-2,346,000	-2,455,000
Other non-operating expense, net	'	'	'	'	'	'	'	'	2,921,000	1,602,000	-2,019,000
Income (loss) before income taxes	'	'	'	'	'	'	'	'	10,347,000	7,752,000	-21,914,000
Capital expenditures	'	'	'	'	'	'	'	'	168,000	3,871,000	6,284,000
Year Ended December 31, 2011	'	'	'	'	'	'	'	'	'	'	'
Settlement for legal dispute	'	'	'	'	'	'	'	'	'	'	-11,100,000
As of December 31, 2013	'	'	'	'	'	'	'	'	'	'	'
Property and equipment, net	1,156,000	'	'	'	1,540,000	'	'	'	1,156,000	1,540,000	'
Identifiable assets, net of intercompany loans and investments	136,973,000	'	'	'	127,796,000	'	'	'	136,973,000	127,796,000	'
Americas [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Research and development revenue	'	'	'	'	'	'	'	'	20,354,000	6,189,000	8,033,000
Product royalty revenue	'	'	'	'	'	'	'	'	52,100,000	50,696,000	41,517,000
Product sales revenue	'	'	'	'	'	'	'	'	556,000	'	'
Co-promotion revenue	'	'	'	'	'	'	'	'	61,000	3,576,000	3,378,000
Contract and collaboration revenue	'	'	'	'	'	'	'	'	566,000	565,000	565,000
Total revenues	'	'	'	'	'	'	'	'	73,637,000	61,026,000	53,493,000
Cost of goods sold	'	'	'	'	'	'	'	'	3,588,000	98,000	'
Research and development expenses	'	'	'	'	'	'	'	'	11,090,000	7,809,000	24,058,000
Depreciation and amortization	'	'	'	'	'	'	'	'	736,000	484,000	791,000
Other operating expenses	'	'	'	'	'	'	'	'	35,911,000	41,410,000	46,326,000
Income (loss) from operations	'	'	'	'	'	'	'	'	22,312,000	11,225,000	-6,582,000
Interest income	'	'	'	'	'	'	'	'	112,000	161,000	240,000
Interest expense	'	'	'	'	'	'	'	'	-1,427,000	'	'
Other non-operating expense, net	'	'	'	'	'	'	'	'	-14,000	77,000	-42,000
Income (loss) before income taxes	'	'	'	'	'	'	'	'	20,983,000	11,463,000	-6,384,000
Capital expenditures	'	'	'	'	'	'	'	'	40,000	401,000	145,000
Year Ended December 31, 2011	'	'	'	'	'	'	'	'	'	'	'
Settlement for legal dispute	'	'	'	'	'	'	'	'	'	'	-11,100,000
As of December 31, 2013	'	'	'	'	'	'	'	'	'	'	'
Property and equipment, net	869,000	'	'	'	1,276,000	'	'	'	869,000	1,276,000	'
Identifiable assets, net of intercompany loans and investments	95,350,000	'	'	'	87,731,000	'	'	'	95,350,000	87,731,000	'
Europe [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Product sales revenue	'	'	'	'	'	'	'	'	62,000	14,000	'
Contract and collaboration revenue	'	'	'	'	'	'	'	'	46,000	16,000	'
Total revenues	'	'	'	'	'	'	'	'	108,000	30,000	'
Cost of goods sold	'	'	'	'	'	'	'	'	15,000	9,000	'
Research and development expenses	'	'	'	'	'	'	'	'	5,445,000	9,571,000	4,354,000
Depreciation and amortization	'	'	'	'	'	'	'	'	716,000	964,000	474,000
Other operating expenses	'	'	'	'	'	'	'	'	5,900,000	2,993,000	1,092,000
Income (loss) from operations	'	'	'	'	'	'	'	'	-11,968,000	-13,507,000	-5,920,000
Interest income	'	'	'	'	'	'	'	'	11,000	16,000	6,000
Interest expense	'	'	'	'	'	'	'	'	-302,000	-2,183,000	-2,288,000
Other non-operating expense, net	'	'	'	'	'	'	'	'	-166,000	-187,000	-1,884,000
Income (loss) before income taxes	'	'	'	'	'	'	'	'	-12,425,000	-15,861,000	-10,086,000
Capital expenditures	'	'	'	'	'	'	'	'	105,000	3,470,000	6,006,000
As of December 31, 2013	'	'	'	'	'	'	'	'	'	'	'
Property and equipment, net	112,000	'	'	'	36,000	'	'	'	112,000	36,000	'
Identifiable assets, net of intercompany loans and investments	23,843,000	'	'	'	25,465,000	'	'	'	23,843,000	25,465,000	'
Asia [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Research and development revenue	'	'	'	'	'	'	'	'	'	15,356,000	1,216,000
Product sales revenue	'	'	'	'	'	'	'	'	15,807,000	5,023,000	'
Contract and collaboration revenue	'	'	'	'	'	'	'	'	42,000	52,000	52,000
Total revenues	'	'	'	'	'	'	'	'	15,849,000	20,431,000	1,268,000
Cost of goods sold	'	'	'	'	'	'	'	'	8,799,000	2,923,000	'
Research and development expenses	'	'	'	'	'	'	'	'	4,989,000	3,912,000	5,085,000
Depreciation and amortization	'	'	'	'	'	'	'	'	36,000	40,000	43,000
Other operating expenses	'	'	'	'	'	'	'	'	3,173,000	2,957,000	1,327,000
Income (loss) from operations	'	'	'	'	'	'	'	'	-1,148,000	10,599,000	-5,187,000
Interest income	'	'	'	'	'	'	'	'	1,000	2,000	3,000
Interest expense	'	'	'	'	'	'	'	'	-165,000	-163,000	-167,000
Other non-operating expense, net	'	'	'	'	'	'	'	'	3,101,000	1,712,000	-93,000
Income (loss) before income taxes	'	'	'	'	'	'	'	'	1,789,000	12,150,000	-5,444,000
Capital expenditures	'	'	'	'	'	'	'	'	23,000	'	133,000
As of December 31, 2013	'	'	'	'	'	'	'	'	'	'	'
Property and equipment, net	175,000	'	'	'	228,000	'	'	'	175,000	228,000	'
Identifiable assets, net of intercompany loans and investments	$17,780,000	'	'	'	$14,600,000	'	'	'	$17,780,000	$14,600,000	'

Note_16_Quarterly_Financial_Da2

Note 16 - Quarterly Financial Data (Unaudited) (Details) - Quarterly Financial Data (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Data [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$24,490	$21,163	$27,023	$16,919	$34,862	$15,496	$16,683	$14,446	$89,594	$81,487	$54,761
Income (loss) from operations	2,679	-1,044	10,169	-2,608	12,966	-1,653	-2,674	-322	9,196	8,317	-17,689
Net income (loss)	$2,153	$1,291	$6,119	($3,145)	$13,532	($5,949)	($819)	($1,928)	$6,419	$4,836	($17,306)
Net income (loss) per share:	'	'	'	'	'	'	'	'	'	'	'
Basic (in Dollars per share)	$0.05	$0.03	$0.15	($0.08)	$0.33	($0.14)	($0.02)	($0.05)	$0.15	$0.12	($0.41)
Diluted (in Dollars per share)	$0.05	$0.03	$0.14	($0.08)	$0.32	($0.14)	($0.02)	($0.05)	$0.15	$0.12	($0.41)

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Valuation and Qualifying Accounts [Abstract]	'	'	'
Valuation Allowance, Deferred Tax Asset, Change in Amount	($2,400,000)	($325,000)	($5,200,000)

Schedule_II_Valuation_and_Qual2

Schedule II - Valuation and Qualifying Accounts (Details) - Valuation and Qualifying Accounts (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Allowance for Doubtful Accounts [Member]	'		'		'
Valuation Allowance [Line Items]	'		'		'
Balance at Beginning of Year	$280		'		'
Additions Charged to Costs and Expenses	160	[1]	280	[1]	'
Balance at End of Year	440		280		'
Valuation Allowance of Deferred Tax Assets [Member]	'		'		'
Valuation Allowance [Line Items]	'		'		'
Balance at Beginning of Year	4,142		4,467		9,658
Additions Charged to Costs and Expenses	'	[2]	1,073	[3]	932	[4]
Deductions	-2,391	[2]	-1,398	[3]	-6,123	[4]
Balance at End of Year	$1,751		$4,142		$4,467

[1]	In 2013 and 2012, the increase in allowance for doubtful accounts is primarily associated with certain disputed Takeda invoices.
[2]	In 2013, the net decrease in valuation allowance of $2.4 million was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized, as well as the reversal of all deferred tax assets of Ambrent for anticipated liquidation.
[3]	In 2012, the net decrease in valuation allowance of $325,000 was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized.
[4]	In 2011, the net decrease in the valuation allowance of $5.2 million was due primarily to the recognition of gains in local tax jurisdictions on the transfer of certain intellectual property to SAG as well as the partial release of valuation allowances in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized.